Neuroactive steroids for the treatment of Alzheimer's disease
Combining NMDA receptor-positive allosteric regulators with anti-amyloid beta antibodies addresses the limitations of current Alzheimer's treatments by enhancing cognitive functions and potentially delaying cognitive decline.
Patent Information
- Application Number
- JP2026207310
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2026-09-16
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for Alzheimer's disease, including those targeting beta-amyloid deposition and tau hyperphosphorylation, have not demonstrated clinical benefit in improving cognitive function and dementia in patients.
Administering NMDA receptor-positive allosteric regulators and anti-amyloid beta antibodies, or their antigen-binding fragments, in combination with pharmaceutically acceptable carriers, to treat or prevent Alzheimer's disease and cognitive impairment.
Improves cognitive functions such as executive function, working memory, and learning in patients with mild cognitive impairment associated with Alzheimer's disease, and potentially delays cognitive decline.
Smart Images

Figure 2026183123000119 
Figure 2026183123000120 
Figure 2026183123000121
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims priority and interest to U.S. Provisional Applications No. 63 / 321,598 filed on 18 March 2022, No. 63 / 289,081 filed on 13 December 2021, and No. 63 / 209,929 filed on 11 June 2021, the disclosures of which are incorporated herein by reference in their entirety. [Background technology]
[0002] Alzheimer's disease (AD) is a progressive, multifactorial neurodegenerative disease that begins with loss of episodic memory and cognitive function, progressing to mild cognitive impairment (MCI) and / or dementia, potentially leading to loss of the ability to continue conversations and respond to the environment. Furthermore, patients with AD-MCI are at high risk of developing dementia, which accounts for the majority of dementia cases. The most common initial symptom is difficulty recalling recent events. As the disease progresses, symptoms may include problems related to language, disorientation, mood swings, apathy, self-abandonment, and behavioral issues. As the condition worsens, individuals with AD often withdraw from family and society. Over time, individuals lose physical function and eventually die.
[0003] Alzheimer's disease (AD) remains without an effective and stable treatment strategy. Currently, available medications for AD are based on symptomatic treatment and focus on managing behavioral and psychological symptoms. Recent clinical studies have investigated treatments that focus on the characteristic underlying pathologies of AD, including beta-amyloid (Aβ) deposition, tau hyperphosphorylation, neuroinflammation, and vascular changes. However, to date, the drugs tested have not demonstrated clinical benefit in terms of improving cognitive function and dementia in AD patients.
[0004] NMDA receptors are highly expressed in the CNS and are involved in excitatory synaptic transmission. Activating these receptors contributes to synaptic plasticity in some situations and excitotoxicity in others. These receptors bind to the neurotransmitters glutamate and glycine after Ca2+12+ 2+ NMDA receptors are ligand-gated ion channels that accept excitatory neurotransmission and underlie normal CNS function. NMDA receptors are heteromeric complexes consisting of NR1, NR2, and / or NR3 subunits, possessing distinctly different recognition sites for exogenous and endogenous ligands. These recognition sites include glycine binding sites, as well as glutamate agonists and regulators. Positive regulators may be useful as therapeutic agents with potential clinical applications as cognitive enhancers and in the treatment of mental disorders in which glutamatergic transmission is reduced or deficient (see, e.g., Horak et al., J. Neuroscience, 2004, 24(46), 10318-10325). Therefore, there remains a need for new and improved therapies for treating Alzheimer's disease. The compositions, kits, and methods disclosed herein are directed to this purpose. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Horak et al.,J.Neuroscience,2004,24(46),10318-10325 [Overview of the Initiative] [Means for solving the problem]
[0006] This specification provides methods for treating Alzheimer's disease, including methods for treating mild cognitive impairment (MCI) or mild dementia associated with Alzheimer's disease.
[0007] In one embodiment, a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject, wherein the formula [ka] Compounds containing A method is provided herein that includes administering a pharmaceutically acceptable salt thereof.
[0008] In some embodiments, compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.
[0009] In one embodiment, a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.
[0010] In one embodiment, a method for improving working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.
[0011] In one embodiment, a method for improving learning in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.
[0012] In one embodiment, a method for improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.
[0013] In one embodiment, a method for treating mild dementia associated with Alzheimer's disease in a subject is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.
[0014] In one embodiment, a method is provided herein for improving executive function in a subject having mild cognitive impairment associated with Alzheimer's disease, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.
[0015] In one embodiment, a method is provided herein for improving working memory in a subject having mild cognitive impairment associated with Alzheimer's disease, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.
[0016] In one aspect, provided herein is a method of improving learning in a subject having mild cognitive impairment associated with Alzheimer's disease in the subject, the method comprising administering Compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.
[0017] In one aspect, provided herein is a method of improving learning and working memory in a subject having mild cognitive impairment associated with Alzheimer's disease in the subject, the method comprising administering Compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.
[0018] In some embodiments, the subject is an adult human. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered as monotherapy. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered in combination with another monotherapy.
[0019] In one embodiment, the present disclosure provides a pharmaceutical composition comprising (a) an NMDA receptor-positive allosteric regulator, (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof, and (c) a pharmaceutically acceptable carrier.
[0020] In one embodiment, the present invention provides a pharmaceutical composition comprising (a) a CYP46A1 inhibitor, (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof, and (c) a pharmaceutically acceptable carrier.
[0021] In one embodiment, the present invention provides a kit comprising a first container, a second container, and an accompanying document, wherein the first container comprises a composition comprising an NMDA receptor-positive allosteric regulator, the second container comprises a composition comprising an anti-amyloid beta antibody or its antigen-binding fragment, and the accompanying document comprises instructions for treating Alzheimer's disease in a subject.
[0022] In one embodiment, the present invention provides a kit comprising a first container, a second container, and an accompanying document, wherein the first container comprises a composition comprising a CYP46A1 inhibitor, the second container comprises a composition comprising an anti-amyloid beta antibody or its antigen-binding fragment, and the accompanying document comprises instructions for treating Alzheimer's disease in a subject.
[0023] In one embodiment, the Disclosure provides a method for treating or preventing Alzheimer's disease, comprising administering to a subject in need of treatment or prevention (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. In some embodiments, the Disclosure provides a method for treating Alzheimer's disease, comprising administering to a subject in need of treatment (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. In some embodiments, the Disclosure provides a method for preventing Alzheimer's disease, comprising administering to a subject in need of prevention (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0024] In one embodiment, the present disclosure is a method for treating or preventing cognitive impairment in a subject having Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. The disclosure provides a method for treating cognitive impairment in a subject having Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. The disclosure also provides a method for preventing cognitive impairment in a subject having Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0025] In one embodiment, the Disclosure provides a method for treating or preventing cognitive impairment caused by Alzheimer's disease in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric modulator and (b) an anti-amyloid-beta antibody or its antigen-binding fragment. In some embodiments, the Disclosure provides a method for treating cognitive impairment caused by Alzheimer's disease in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric modulator and (b) an anti-amyloid-beta antibody or its antigen-binding fragment. In some embodiments, the Disclosure provides a method for preventing cognitive impairment caused by Alzheimer's disease in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric modulator and (b) an anti-amyloid-beta antibody or its antigen-binding fragment. In some embodiments, the cognitive impairment is mild cognitive impairment.
[0026] In one embodiment, the present disclosure provides a method for improving cognition in a subject having Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0027] In one embodiment, the present disclosure provides a method for delaying cognitive decline caused by Alzheimer's disease in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0028] In one embodiment, the present disclosure provides a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0029] In one embodiment, the present disclosure provides a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0030] In one embodiment, the present disclosure provides a method for improving working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0031] In one embodiment, the present disclosure provides a method for improving learning in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric modulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0032] In one aspect, the disclosure relates to a person with mild cognitive impairment (MCI) associated with Alzheimer's disease. The present invention provides a method for improving learning and working memory in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or its antigen-binding fragment.
[0033] In one embodiment, the present disclosure provides a method for treating mild dementia associated with Alzheimer's disease in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0034] In one embodiment, the present disclosure provides a method for improving executive function in a subject having mild dementia associated with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0035] In one embodiment, the present disclosure provides a method for improving working memory in a subject having mild dementia associated with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0036] In one embodiment, the present disclosure provides a method for improving learning in a subject having mild cognitive impairment associated with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0037] In one embodiment, the present disclosure provides a method for improving learning and working memory in a subject with mild cognitive impairment associated with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0038] In one embodiment, the present disclosure provides a method for treating or preventing Alzheimer's disease, comprising administering (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof to a subject in need of treatment or prevention. In some embodiments, the present disclosure provides a method for treating Alzheimer's disease, comprising administering (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof to a subject in need of treatment or prevention. In some embodiments, the present disclosure provides a method for treating Alzheimer's disease, comprising administering (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof to a subject in need of treatment or prevention.
[0039] In one embodiment, the Disclosure provides a method for treating or preventing cognitive impairment in a subject having Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. In some embodiments, the Disclosure provides a method for treating cognitive impairment in a subject having Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. In some embodiments, the Disclosure provides a method for preventing cognitive impairment in a subject having Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0040] In one aspect, the disclosure relates to the treatment of cognitive impairment caused by Alzheimer's disease in the subject or The present disclosure provides a method for prevention, comprising administering to a subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. In some embodiments, the present disclosure provides a method for treating cognitive impairment resulting from Alzheimer's disease in a subject, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. In some embodiments, the present disclosure provides a method for preventing cognitive impairment resulting from Alzheimer's disease in a subject, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. In some embodiments, the cognitive impairment is mild cognitive impairment.
[0041] In one embodiment, the present disclosure provides a method for improving cognition in a subject having Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0042] In one embodiment, the present disclosure provides a method for delaying cognitive decline caused by Alzheimer's disease in a subject, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0043] In one embodiment, the present disclosure provides a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0044] In one embodiment, the present disclosure provides a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0045] In one embodiment, the present disclosure provides a method for improving working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0046] In one embodiment, the present disclosure provides a method for improving learning in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0047] In one embodiment, the present disclosure provides a method for improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease, the method comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0048] In one embodiment, the present disclosure provides a method for treating mild dementia associated with Alzheimer's disease in a subject, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0049] In one embodiment, the present disclosure provides a method for improving executive function in a subject having mild dementia associated with Alzheimer's disease, the method comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0050] In one embodiment, the present disclosure provides a method for improving working memory in a subject having mild dementia associated with Alzheimer's disease, the method comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0051] In one embodiment, the disclosure provides a method for improving learning in a subject having mild cognitive impairment associated with Alzheimer's disease, the method comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0052] In one embodiment, the present disclosure provides a method for improving learning and working memory in a subject having mild cognitive impairment associated with Alzheimer's disease, the method comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof.
[0053] In some embodiments, the NMDA receptor-positive allosteric regulators include 9-iodophenanthrene-3-carboxylic acid (UBP512), 6-(4-methylpentyl)naphthalene-2-carboxylic acid (UBP684), 4-cyclohexyl-N-(7-hydroxy-5-methyl-2-propyl[1,2,4]triazolo[1,5-a]pyrimidine-6-yl)benzenesulfonamide (GNE-9278), 2-butyl-7-(((ethyl(phenyl)amino)methyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidine-5-one (GNE-3476), and 4-(4-hydroxy-1-(2-(6-methyl-1H-indole-3-yl)ethyl)-3-nicotinotinoyl-5-oxo-2,5-dihydro-1H-pyrrole-2-yl)benzoate methyl (PYD-111), 4-(3-acetyl-4-hydroxy-1-(2-(2-methyl-1H-indole-3-yl)ethyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-yl)benzoate methyl (PYD-106), 3-chlorophenyl)(6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline-2(1H)-yl) The following are selected from the group consisting of metanon (CIQ), NYX-458, and plazinemdor (5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidine-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidine-4-one) and pharmaceutically acceptable salts thereof.
[0054] In some embodiments, the NMDA receptor-positive allosteric modulator is a neuroactive steroid or a pharmaceutically acceptable salt thereof. In some embodiments, the neuroactive steroid is selected from any one of compounds B1 to B543 and its pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from any one of compounds B1 to B140 and its pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from any one of compounds B150 to B245 and its pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from any one of compounds B273 to B349 and its pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from any one of compounds B395 to B432 and its pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B433 to B443 and its pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B444 to B451 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B452 to B477 and their pharmaceutically acceptable salts. The neuroactive steroid is selected from the group consisting of pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B478 to B530 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B531 to B543 and their pharmaceutically acceptable salts.
[0055] In some embodiments, the CYP46A1 inhibitor is selected from the group consisting of TAK-935, one of compounds A1 to A182, and pharmaceutically acceptable salts thereof. In some embodiments, the CYP46A1 inhibitor is selected from the group consisting of TAK-935, any one of compounds A1 to A125, and pharmaceutically acceptable salts thereof. In some embodiments, the CYP46A1 inhibitor is TAK-935 or a pharmaceutically acceptable salt thereof. In some embodiments, the CYP46A1 inhibitor is selected from the group consisting of any one of compounds A1 to A125, and pharmaceutically acceptable salts thereof. In some embodiments, the CYP46A1 inhibitor is selected from the group consisting of any one of compounds A126 to A182, and pharmaceutically acceptable salts thereof.
[0056] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is selected from the group consisting of bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), aducanumab, and their antigen-binding fragments.
[0057] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is (a) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 1, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 2, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 3, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 4, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 5, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 6, (b) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 11, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 12, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 13, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 14, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 15, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 16, (c) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 21, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 22, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 23, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 24, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 25, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 26, (d) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 31, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 32, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 34, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 36, (e) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 41, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 42, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 43, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 44, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 45, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 46, (f) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 51, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 52, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 53, and (i) the amino acid sequence of SEQ ID NO: 54 A light chain variable domain (VL) comprising (ii) LCDR1, LCDR2 containing the amino acid sequence of SEQ ID NO: 55, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 56, or (g) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 61, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 62, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 63, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 64, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 65, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 66.
[0058] In some embodiments, an anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) comprising (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) an HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and (iii) an HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable domain (VL) comprising (b) an LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, (ii) an LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and (iii) an LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.
[0059] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) comprising (a) the amino acid sequence of SEQ ID NO: 7, (b) the amino acid sequence of SEQ ID NO: 17, (c) the amino acid sequence of SEQ ID NO: 27, (d) the amino acid sequence of SEQ ID NO: 37, (e) the amino acid sequence of SEQ ID NO: 47, (f) the amino acid sequence of SEQ ID NO: 57, or (g) the amino acid sequence of SEQ ID NO: 67.
[0060] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) comprising (a) the amino acid sequence of SEQ ID NO: 8, (b) the amino acid sequence of SEQ ID NO: 18, (c) the amino acid sequence of SEQ ID NO: 28, (d) the amino acid sequence of SEQ ID NO: 38, (e) the amino acid sequence of SEQ ID NO: 48, (f) the amino acid sequence of SEQ ID NO: 58, or (g) the amino acid sequence of SEQ ID NO: 68.
[0061] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 7. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 7, and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 8.
[0062] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a constant domain of human IgG1, IgG2, IgG3, or IgG4. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a constant region of human IgG1.
[0063] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is a human anti-amyloid beta antibody or its antigen-binding fragment.
[0064] In some embodiments, the antigen-binding fragment is a single-chain antibody, Fv, Fab, Fab', F(ab')2, Fd, a single-chain Fv molecule (scFv), a bispecific single-chain Fv dimer, a diabody, a domain deletion antibody, or a single-domain antibody (dAb).
[0065] In some embodiments, the anti-amyloid beta antibody is (a) the amino acid sequence of SEQ ID NO: 9, (b) the amino acid sequence of SEQ ID NO: 19, (c) the amino acid sequence of SEQ ID NO: 29, (d) the amino acid sequence of SEQ ID NO: 39, (e) the amino acid sequence of SEQ ID NO: 49, (f) the amino acid sequence of SEQ ID NO: 59 The heavy chain contains an amino acid sequence, or (g) the amino acid sequence of SEQ ID NO: 69.
[0066] In some embodiments, the anti-amyloid-beta antibody includes a light chain comprising (a) the amino acid sequence of SEQ ID NO: 10, (b) the amino acid sequence of SEQ ID NO: 20, (c) the amino acid sequence of SEQ ID NO: 30, (d) the amino acid sequence of SEQ ID NO: 40, (e) the amino acid sequence of SEQ ID NO: 50, (f) the amino acid sequence of SEQ ID NO: 60, or (g) the amino acid sequence of SEQ ID NO: 70.
[0067] In some embodiments, the anti-amyloid-beta antibody includes a heavy chain containing the amino acid sequence of SEQ ID NO: 9.
[0068] In some embodiments, the anti-amyloid-beta antibody includes a light chain containing the amino acid sequence of SEQ ID NO: 10.
[0069] In some embodiments, the anti-amyloid-beta antibody is aducanumab. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which aducanumab binds.
[0070] In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment competitively inhibits the binding of aducanumab to amyloid-beta. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to amyloid-beta plaques, parenchymal amyloid, vascular amyloid, or diffuse amyloid-beta deposits.
[0071] In some embodiments, the NMDA receptor-positive allosteric regulator and the anti-amyloid beta antibody or its antigen-binding fragment are administered simultaneously. In some embodiments, the NMDA receptor-positive allosteric regulator and the anti-amyloid beta antibody or its antigen-binding fragment are administered sequentially. In some embodiments, the NMDA receptor-positive allosteric regulator and the anti-amyloid beta antibody or its antigen-binding fragment are administered separately. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is administered before the NMDA receptor-positive allosteric regulator. In some embodiments, the NMDA receptor-positive allosteric regulator is administered before the anti-amyloid beta antibody or its antigen-binding fragment. In some embodiments, the administration frequency of the anti-amyloid beta antibody or its antigen-binding fragment and the NMDA receptor-positive allosteric regulator is the same. In some embodiments, the administration frequency of the anti-amyloid beta antibody or its antigen-binding fragment and the NMDA receptor-positive allosteric regulator is different.
[0072] In some embodiments, the CYP46A1 inhibitor and the anti-amyloid beta antibody or its antigen-binding fragment are administered simultaneously. In some embodiments, the CYP46A1 inhibitor and the anti-amyloid beta antibody or its antigen-binding fragment are administered sequentially. In some embodiments, the CYP46A1 inhibitor and the anti-amyloid beta antibody or its antigen-binding fragment are administered separately. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is administered before the CYP46A1 inhibitor. In some embodiments, the CYP46A1 inhibitor is administered before the anti-amyloid beta antibody or its antigen-binding fragment. In some embodiments, the administration frequency of the anti-amyloid beta antibody or its antigen-binding fragment and the CYP46A1 inhibitor is the same. In some embodiments, the administration frequency of the anti-amyloid beta antibody or its antigen-binding fragment and the CYP46A1 inhibitor is different. The present invention provides, for example, the following items: (Item 1) A method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 2) A method for improving executive function in a subject with mild cognitive impairment (MCI) associated with Alzheimer's disease, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 3) A method for improving working memory in a subject with mild cognitive impairment (MCI) associated with Alzheimer's disease, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 4) A method for improving learning in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 5) A method for improving learning and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 6) A method for treating mild dementia associated with Alzheimer's disease in a subject, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 7) A method for improving executive function in a subject with mild dementia associated with Alzheimer's disease, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 8) A method for improving working memory in a subject with mild cognitive impairment associated with Alzheimer's disease, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 9) A method for improving learning in subjects with mild cognitive impairment associated with Alzheimer's disease, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 10) A method for improving learning and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease, wherein the subject is given the formula [ka] A method comprising administering a compound having or a pharmaceutically acceptable salt thereof. (Item 11) The method according to any one of items 1 to 10, wherein compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject daily. (Item 12) The method according to any one of items 1 to 11, wherein compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. (Item 13) The method according to item 12, wherein approximately 3 mg of compound 1 is administered to the subject per day. (Item 14) The method according to any one of items 1 to 13, wherein compound 1 or a pharmaceutically acceptable salt thereof is administered orally. (Item 15) The method described in any one of items 1 to 14, wherein the subject is an adult. (Item 16) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in the treatment of mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject, or a pharmaceutically acceptable salt thereof. (Item 17) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (Item 18) formula [ka] Compounds having, or pharmaceutically acceptable salts thereof, for use in improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (Item 19) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in improving learning in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (Item 20) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in improving learning and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (Item 21) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in the treatment of mild dementia associated with Alzheimer's disease in a subject, or a pharmaceutically acceptable salt thereof. (Item 22) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in improving executive function in subjects with mild cognitive impairment associated with Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (Item 23) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in improving working memory in subjects with mild cognitive impairment associated with Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (Item 24) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in improving learning in subjects with mild cognitive impairment associated with Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (Item 25) formula [ka] A compound having, or a pharmaceutically acceptable salt thereof, for use in improving learning and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (Item 26) Compound 1 or a pharmaceutically acceptable salt thereof is administered daily to the subject, and is a compound for use as described in any one of items 16 to 25. (Item 27) Compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day, as described in any one of items 16 to 26. (Item 28) Compound 1 for use as described in item 27, administered to the subject at a dose of approximately 3 mg per day. (Item 29) Compound 1 or a pharmaceutically acceptable salt thereof is a compound for use as described in any one of items 16 to 28, administered orally. (Item 30) The compound for use described in any one of items 16 to 29, wherein the subject is an adult. (Item 31) formula [ka] The use of a compound having, or a pharmaceutically acceptable salt thereof, a) Treatment of mild cognitive impairment (MCI) associated with Alzheimer's disease in the target population. b) Improvement of executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease, c) Improvement of working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. d) Improvement of learning in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease, or e) Use for the manufacture of drugs to improve learning and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. (Item 32) formula [ka] The use of a compound having, or a pharmaceutically acceptable salt thereof, a) Treatment of mild dementia associated with Alzheimer's disease in the subjects, b) Improvement of executive function in subjects with mild cognitive impairment associated with Alzheimer's disease, c) Improvement of working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. d) Improvement of learning in subjects with mild cognitive impairment associated with Alzheimer's disease, or e) Use for the manufacture of drugs to improve learning and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. (Item 33) The use described in item 31 or 32, wherein compound 1 or a pharmaceutically acceptable salt thereof is administered daily to the subject. (Item 34) The use described in any one of items 31 to 33, wherein compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. (Item 35) The use described in item 34 involves administering approximately 3 mg of compound 1 per day to the subject. (Item 36) Compound 1 or a pharmaceutically acceptable salt thereof is administered orally, as described in any one of items 31 to 35. (Item 37) A pharmaceutical composition, (a) NMDA receptor-positive allosteric regulators, (b) an anti-amyloid beta antibody or its antigen-binding fragment, (c) A pharmaceutical composition comprising a pharmaceutically acceptable carrier. (Item 38) A pharmaceutical composition, (a) CYP46A1 inhibitors, (b) an anti-amyloid beta antibody or its antigen-binding fragment, (c) A pharmaceutical composition comprising a pharmaceutically acceptable carrier. (Item 39) The pharmaceutical composition according to item 37 or 38, wherein the anti-amyloid beta antibody or its antigen-binding fragment is selected from the group consisting of bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), aducanumab, and their antigen-binding fragments. (Item 40) The pharmaceutical composition according to any one of items 37 to 39, wherein the anti-amyloid beta antibody or its antigen-binding fragment comprises a constant domain of human IgG1, IgG2, IgG3, or IgG4. (Item 41) The pharmaceutical composition according to item 40, wherein the anti-amyloid beta antibody or its antigen-binding fragment comprises a human IgG1 constant region. (Item 42) The pharmaceutical composition according to any one of items 37 to 41, wherein the anti-amyloid beta antibody or its antigen-binding fragment is a human anti-amyloid beta antibody or its antigen-binding fragment. (Item 43) The pharmaceutical composition according to any one of items 37 to 42, wherein the antigen-binding fragment is a single-chain antibody, Fv, Fab, Fab', F(ab')2, Fd, a single-chain Fv molecule (scFv), a bispecific single-chain Fv dimer, a diabody, a domain deletion antibody, or a single-domain antibody (dAb). (Item 44) The anti-amyloid beta antibody or its antigen-binding fragment is used to target amyloid beta plaques, A pharmaceutical composition according to any one of items 37 to 43, which binds to cerebrovascular amyloid, vascular amyloid, or diffuse amyloid-beta deposits. (Item 45) The aforementioned NMDA receptor-positive allosteric regulators include 9-iodophenanthrene-3-carboxylic acid (UBP512), 6-(4-methylpentyl)naphthalene-2-carboxylic acid (UBP684), 4-cyclohexyl-N-(7-hydroxy-5-methyl-2-propyl[1,2,4]triazolo[1,5-a]pyrimidine-6-yl)benzenesulfonamide (GNE-9278), and 2-buty Ru-7-(((ethyl(phenyl)amino)methyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidine-5-one (GNE-3476), 4-(4-hydroxy-1-(2-(6-methyl-1H-indole-3-yl)ethyl)-3-nicotinotinoyl-5-oxo-2,5-dihydro-1H-pyrrole-2-yl)benzoate methyl (PYD-111), 4-(3-acetyl -4-Hydroxy-1-(2-(2-methyl-1H-indole-3-yl)ethyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-yl)benzoate methyl (PYD-106), 3-chlorophenyl)(6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline-2(1H)-yl)methanone (CIQ), NYX-458, and Prazinem A pharmaceutical composition according to any one of items 37 or 39-44, selected from the group consisting of plazinemdor (5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidine-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidine-4-one) and pharmaceutically acceptable salts thereof. (Item 46) The pharmaceutical composition according to any one of items 37 or 39-45, wherein the NMDA receptor-positive allosteric regulator is a neuroactive steroid or a pharmaceutically acceptable salt thereof. (Item 47) The pharmaceutical composition according to item 46, wherein the neuroactive steroid is selected from any one of compounds B1 to B543 and pharmaceutically acceptable salts thereof. (Item 48) The pharmaceutical composition according to any one of items 38 to 44, wherein the CYP46A1 inhibitor is selected from the group consisting of TAK-935, one of compounds A1 to A182, and a pharmaceutically acceptable salt thereof. (Item 49) The pharmaceutical composition according to item 48, wherein the CYP46A1 inhibitor is TAK-935 or a pharmaceutically acceptable salt thereof. (Item 50) The pharmaceutical composition according to item 48, wherein the CYP46A1 inhibitor is selected from the group consisting of one of compounds A1 to A182 and a pharmaceutically acceptable salt thereof. (Item 51) A kit comprising a first container, a second container, and an accompanying document, The first container contains a composition comprising an NMDA receptor-positive allosteric regulator, A kit comprising a second container containing a composition comprising an anti-amyloid-beta antibody or an antigen-binding fragment thereof, wherein the accompanying leaflet contains instructions for treating Alzheimer's disease in a subject. (Item 52) A kit comprising a first container, a second container, and an accompanying document, The first container contains a composition comprising a CYP46A1 inhibitor, A kit comprising a second container containing a composition comprising an anti-amyloid-beta antibody or an antigen-binding fragment thereof, wherein the accompanying leaflet contains instructions for treating Alzheimer's disease in a subject. (Item 53) A method for treating or preventing Alzheimer's disease, which requires treatment or prevention. A method comprising administering to a subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or its antigen-binding fragment. (Item 54) A method for treating or preventing cognitive impairment in a subject with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. (Item 55) A method for treating or preventing cognitive impairment caused by Alzheimer's disease in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. (Item 56) A method for improving cognition in a subject with Alzheimer's disease, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. (Item 57) A method for delaying cognitive decline caused by Alzheimer's disease in a subject, comprising administering to the subject (a) an NMDA receptor-positive allosteric regulator and (b) an anti-amyloid beta antibody or its antigen-binding fragment. (Item 58) A method for treating or preventing Alzheimer's disease, comprising administering to a subject in need of treatment or prevention (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. (Item 59) A method for treating or preventing cognitive impairment in a subject having Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. (Item 60) A method for treating or preventing cognitive impairment caused by Alzheimer's disease in a subject, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. (Item 61) A method for improving cognition in a subject with Alzheimer's disease, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. (Item 62) A method for delaying cognitive decline caused by Alzheimer's disease in a subject, comprising administering to the subject (a) a CYP46A1 inhibitor and (b) an anti-amyloid beta antibody or an antigen-binding fragment thereof. (Item 63) The method according to any one of items 53 to 62, wherein the anti-amyloid beta antibody or its antigen-binding fragment is selected from the group consisting of bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), aducanumab, and their antigen-binding fragments. (Item 64) The method according to any one of items 53 to 63, wherein the anti-amyloid beta antibody or its antigen-binding fragment comprises a constant domain of human IgG1, IgG2, IgG3, or IgG4. (Item 65) The method according to item 64, wherein the anti-amyloid beta antibody or its antigen-binding fragment comprises a human IgG1 constant region. (Item 66) The method according to any one of items 53 to 65, wherein the anti-amyloid beta antibody or its antigen-binding fragment is a human anti-amyloid beta antibody or its antigen-binding fragment. (Item 67) The method according to any one of items 53 to 66, wherein the antigen-binding fragment is a single-chain antibody, Fv, Fab, Fab', F(ab')2, Fd, a single-chain Fv molecule (scFv), a bispecific single-chain Fv dimer, a diabody, a domain deletion antibody, or a single-domain antibody (dAb). (Item 68) The method according to any one of items 53 to 67, wherein the anti-amyloid beta antibody or its antigen-binding fragment binds to amyloid beta plaque, parenchymal amyloid, cerebral vascular amyloid, or diffuse amyloid beta deposits. (Item 69) The aforementioned NMDA receptor-positive allosteric regulators are 9-iodophenanthrene-3-carboxylic acid (UBP512), 6-(4-methylpentyl)naphthalene-2-carboxylic acid (UBP684), 4-cyclohexyl-N-(7-hydroxy-5-methyl-2-propyl[1,2,4]triazolo[1,5-a]pyrimidine-6-yl)benzenesulfonamide (GNE-9278), and 2- Tyl-7-(((ethyl(phenyl)amino)methyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidine-5-one (GNE-3476), 4-(4-hydroxy-1-(2-(6-methyl-1H-indole-3-yl)ethyl)-3-nicotinotinoyl-5-oxo-2,5-dihydro-1H-pyrrole-2-yl)benzoate methyl (PYD-111), 4-(3-acetyl Methyl 4-hydroxy-1-(2-(2-methyl-1H-indole-3-yl)ethyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-yl)benzoate (PYD-106), 3-chlorophenyl)(6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline-2(1H)-yl)methanone (CIQ), NYX-458, and Pragnet The method according to any one of items 53-57 or 63-68, selected from the group consisting of plazinemdor (5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidine-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidine-4-one) and pharmaceutically acceptable salts thereof. (Item 70) The method according to any one of items 53-57 or 63-69, wherein the NMDA receptor-positive allosteric regulator is a neuroactive steroid or a pharmaceutically acceptable salt thereof. (Item 71) The method according to item 70, wherein the neuroactive steroid is selected from any one of compounds B1 to B543 and pharmaceutically acceptable salts thereof. (Item 72) The method according to any one of items 53-57 or 63-71, wherein the NMDA receptor-positive allosteric regulator and the anti-amyloid beta antibody or its antigen-binding fragment are administered simultaneously. (Item 73) The method according to any one of items 53-57 or 63-72, wherein the NMDA receptor-positive allosteric regulator and the anti-amyloid beta antibody or its antigen-binding fragment are administered sequentially. (Item 74) The method according to any one of items 53-57 or 63-72, wherein the NMDA receptor-positive allosteric regulator and the anti-amyloid beta antibody or its antigen-binding fragment are administered separately. (Item 75) The method according to item 73 or 74, wherein the anti-amyloid beta antibody or its antigen-binding fragment is administered before the NMDA receptor-positive allosteric regulator. (Item 76) The method according to item 73 or 74, wherein the NMDA receptor-positive allosteric regulator is administered before the anti-amyloid beta antibody or its antigen-binding fragment. (Item 77) The method according to any one of items 53-57 or 63-76, wherein the frequency of administration of the anti-amyloid beta antibody or its antigen-binding fragment and the NMDA receptor-positive allosteric regulator is the same. (Item 78) The method according to any one of items 53-57 or 63-76, wherein the frequency of administration of the anti-amyloid beta antibody or its antigen-binding fragment and the NMDA receptor-positive allosteric regulator differs. (Item 79) The method according to any one of items 58 to 68, wherein the CYP46A1 inhibitor is selected from the group consisting of TAK-935, one of compounds A1 to A182, and a pharmaceutically acceptable salt thereof. (Item 80) The method according to item 79, wherein the CYP46A1 inhibitor is TAK-935 or a pharmaceutically acceptable salt thereof. (Item 81) The method according to item 79, wherein the CYP46A1 inhibitor is selected from the group consisting of one of compounds A1 to A182 and a pharmaceutically acceptable salt thereof. (Item 82) The method according to any one of items 58-68 or 79-81, wherein the CYP46A1 inhibitor and the anti-amyloid beta antibody or its antigen-binding fragment are administered simultaneously. (Item 83) The method according to any one of items 58-68 or 79-81, wherein the CYP46A1 inhibitor and the anti-amyloid beta antibody or its antigen-binding fragment are administered sequentially. (Item 84) The method according to any one of items 58-68 or 79-81, wherein the CYP46A1 inhibitor and the anti-amyloid beta antibody or its antigen-binding fragment are administered separately. (Item 85) The method according to item 83 or 84, wherein the anti-amyloid beta antibody or its antigen-binding fragment is administered before the CYP46A1 inhibitor. (Item 86) The method according to item 83 or 84, wherein the CYP46A1 inhibitor is administered before the anti-amyloid beta antibody or its antigen-binding fragment. (Item 87) The method according to any one of items 58-68 or 79-86, wherein the frequency of administration of the anti-amyloid beta antibody or its antigen-binding fragment and the CYP46A1 inhibitor is the same. (Item 88) The method according to any one of items 58-68 or 79-86, wherein the frequency of administration of the anti-amyloid beta antibody or its antigen-binding fragment and the CYP46A1 inhibitor differs. (Item 89) (a) the use of an NMDA receptor-positive allosteric regulator, and (b) an anti-amyloid beta antibody or its antigen-binding fragment, (i) Treatment or prevention of Alzheimer's disease in the subject (ii) Treatment or prevention of cognitive impairment in persons with Alzheimer's disease, (iii) Treatment or prevention of cognitive impairment caused by Alzheimer's disease in the subject (iv) Improvement of cognition in subjects with Alzheimer's disease, (v) Use for the manufacture of drugs for delaying cognitive decline caused by Alzheimer's disease in subjects. (Item 90) (a) the use of a CYP46A1 inhibitor, and (b) an anti-amyloid beta antibody or its antigen-binding fragment, (i) Treatment or prevention of Alzheimer's disease in the subject (ii) Treatment or prevention of cognitive impairment in persons with Alzheimer's disease, (iii) Treatment or prevention of cognitive impairment caused by Alzheimer's disease in the subject (iv) Improvement of cognition in subjects with Alzheimer's disease, (v) Use for the manufacture of drugs for delaying cognitive decline caused by Alzheimer's disease in subjects. (Item 91) An NMDA receptor-positive allosteric regulator, and an anti-amyloid beta antibody or its antigen-binding fragment, for use in the treatment or prevention of Alzheimer's disease in the target population. (Item 92) An NMDA receptor-positive allosteric regulator, and an anti-amyloid beta antibody or its antigen-binding fragment, for use in the treatment or prevention of cognitive impairment in subjects with Alzheimer's disease. (Item 93) An NMDA receptor-positive allosteric regulator, and an anti-amyloid beta antibody or its antigen-binding fragment, for use in the treatment or prevention of cognitive impairment caused by Alzheimer's disease in the target population. (Item 94) An NMDA receptor-positive allosteric regulator, and an anti-amyloid beta antibody or its antigen-binding fragment, for use in improving cognition in subjects with Alzheimer's disease. (Item 95) An NMDA receptor-positive allosteric regulator, and an anti-amyloid beta antibody or its antigen-binding fragment, for use in delaying cognitive decline caused by Alzheimer's disease in the target population. (Item 96) A CYP46A1 inhibitor and an anti-amyloid beta antibody or its antigen-binding fragment for use in the treatment or prevention of Alzheimer's disease in the target population. (Item 97) A CYP46A1 inhibitor, and an anti-amyloid beta antibody or its antigen-binding fragment, for use in the treatment or prevention of cognitive impairment in subjects with Alzheimer's disease. (Item 98) A CYP46A1 inhibitor and an anti-amyloid beta antibody or its antigen-binding fragment for use in the treatment or prevention of cognitive impairment caused by Alzheimer's disease in the target population. (Item 99) A CYP46A1 inhibitor and an anti-amyloid beta antibody or its antigen-binding fragment for use in improving cognition in subjects with Alzheimer's disease. (Item 100) A CYP46A1 inhibitor and an anti-amyloid beta antibody or its antigen-binding fragment for use in delaying cognitive decline caused by Alzheimer's disease in the target population. [Brief explanation of the drawing]
[0073] [Figure 1] The research design is outlined below. [Figure 2] This shows baseline executive function deficits in AD patients as measured using the digit substitution test. [Figure 3] This shows baseline learning and memory in AD patients as measured by pattern recognition memory (PRM). [Figure 4] This shows baseline attention and psychomotor velocity in AD patients as measured by reaction time (RT). [Figure 5] This shows executive function in AD patients as measured using the 2-BAC test. [Figure 6]This shows executive function in AD patients as measured using MTT. [Figure 7] This shows learning and memory in AD patients as measured using VRM (Free Recall) testing. [Figure 8] This shows learning and memory in AD patients as measured using the PRM (Percentage-Relaxed Response) test. [Modes for carrying out the invention]
[0074] Generally as described herein, the present invention provides compositions, kits, and methods for treating various CNS diseases and disorders in patients requiring treatment for them.
[0075] definition The term "Specified Use" refers to the entirety of this application.
[0076] Unless otherwise defined herein, scientific and technical terms used in this application have meanings that are generally understood by those skilled in the art. In general, the terms used in relation to the compounds, compositions and methods described herein are well known and commonly used in the art.
[0077] It should be understood that any embodiment described herein, including those described under different aspects of this disclosure and different parts thereof (including embodiments described only in the Examples section), can be combined with one or more other embodiments of the Invention unless expressly disclaimed or inappropriate. The combinations of embodiments are not limited to those specific combinations claimed through the scope of any of the dependent claims.
[0078] All publications, patents, and published patent applications referenced herein are incorporated herein by reference in their entirety. In the event of any conflict, this specification shall prevail, including its specific definitions.
[0079] Definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are listed in Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75. th Identified according to the Ed., inside cover, specific functional groups are generally defined as described therein. In addition, general principles of organic chemistry, as well as specific functional parts and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999, and Smith and March, March's Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001, Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989, and Carruthers, Some Modern Methods of Organic Synthesis, 3. rd This information is found in Edition, Cambridge University Press, Cambridge, 1987.
[0080] Standard techniques can be used for chemical synthesis and antibody production. These and related techniques and procedures are Generally, these procedures may be carried out in accordance with conventional methods well known in the art and as described in the various general and more specific references cited and discussed throughout this specification. Unless otherwise specified, the terms used herein in relation to molecular biology, analytical chemistry, synthetic organic chemistry, and pharmaceutical and medicinal chemistry, as well as their laboratory procedures and techniques, are well known and commonly used in the art. Standard techniques may be used in recombinant techniques, molecular biological, microbiological, chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, and delivery, and in the treatment of subjects.
[0081] Throughout this specification, the word “comprise,” or variations such as “comprises” or “comprising,” shall be understood to imply the inclusion of the element (or component) or group of elements (or components) being described, but not the exclusion of any other element (or component) or group of elements (or components).
[0082] Throughout this specification, where a composition is described as having, including, or comprising (or variations thereof) specific components, it is intended that the composition is essentially composed of, or may be composed of, the listed components. Similarly, where a method or process is described as having, including, or comprising specific process steps, the process is essentially composed of, or may be composed of, the listed processing steps. Furthermore, it should be understood that the order of steps or the order in which certain operations are performed is not important, as long as the compositions and methods described herein remain operational. Moreover, two or more steps or operations can be performed simultaneously.
[0083] As used herein, the term "including" means "including but not limited to." "Including" and "including but not limited to" are used interchangeably. Therefore, these terms should be understood to imply the inclusion of the described element(s) or group of elements(s) but not the exclusion of any other element(s) or group of elements(s).
[0084] As used herein, the terms “about” or “approximately” mean within a tolerance range for a particular value as determined by those skilled in the art, which in part depends on how that value is measured or determined, i.e., the limits of the measuring system.
[0085] Unless otherwise required by the context, singular terms shall include the plural form, and plural terms shall include the singular form.
[0086] In the context describing elements (particularly in the context of the following claims), the use of the terms “a,” “an,” and “the,” and similar reference subjects, should be interpreted as encompassing both singular and plural forms, unless otherwise indicated herein or unless the context clearly contradicts this interpretation.
[0087] As used herein, the term "or" should be understood to mean "and / or" unless the context explicitly indicates otherwise.
[0088] References to ranges of values in this Specified are intended simply as a way of individually referring to each distinct value that falls within a range, unless otherwise indicated herein, and each distinct value is incorporated herein as if it were individually referred to herein. Furthermore, all scopes disclosed herein should be understood to encompass all sub-scopes contained within them. For example, a scope described as "1 to 10" should be considered to include all sub-scopes between the minimum value of 1 and the maximum value of 10 (including these values), i.e., all sub-scopes starting from a minimum value of 1 or greater, e.g., 1 to 6.1, and ending from a maximum value of 10 or less, e.g., 5.5 to 10. Disclosure of a scope should also be considered a disclosure of the endpoints of that scope.
[0089] All methods described herein may be carried out in any preferred order, unless otherwise indicated herein or unless the context clearly contradicts it.
[0090] Any examples or illustrative language provided herein (e.g., "etc.") are intended solely to better illustrate embodiments and, unless otherwise stated, do not constitute a limitation of the claims. Nothing in this specification should be construed as indicating that any non-claimed element is essential.
[0091] The terms “antibody” (Ab) and “immunoglobulin” (Ig) are used interchangeably herein and refer to molecules (e.g., complete antibodies, antibody fragments, or modified antibodies) capable of recognizing and binding to specific targets or antigens, such as carbohydrates, polynucleotides, lipids, and polypeptides, through at least one antigen-recognition site located in the variable region of the molecule. Antibodies may be membrane-bound or secreted. As used herein, the terms encompass not only intact or “whole,” polyclonal or monoclonal antibodies, but also their fragments (single variable domain (VH, VL, or combination thereof) antibodies, Fab, Fab', F(ab')2, Fv), single-chain (ScFv), their synthetic variants, naturally occurring variants, fusion proteins containing an antibody moiety with an antigen-binding fragment of the required specificity, humanized antibodies, chimeric antibodies, chimeric antigen receptors (CARs), and any other modified configurations of immunoglobulin molecules containing an antigen-binding site or fragment (epitope-recognition site) of the required specificity.
[0092] Antibodies, or Ig molecules, typically consist of two heavy chains and two light chains linked together via disulfide bonds. Both the heavy chains (IgH) and light chains (IgL) contain a variable (V) region or domain and a constant (C) region or domain. The portion of the IgH locus encoding the V region contains multiple copies of the variable (V), diverse (D), and conjugation (J) gene fragments. The portion of the IgL locus encoding the V region contains multiple copies of the V and J gene fragments. The V region encoding portions of the IgH and IgL loci undergo gene fragment rearrangements, e.g., different combinations of the V, (D), and J gene fragments, to form the IgH and IgL variable regions (VH and VL, respectively), developing diverse antigen specificity in antibodies. Each variable region contains three hypervariable complementarity-determining regions (CDRs) interspersed among low-variability framework regions (FRs). The fully variable domain, if present, contains four framework regions (FRs) and three complementarity-determining regions (CDRs), which, if present, are sequenced in the order FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4, starting from the amino terminus. CDR boundaries can be identified by visual inspection and sequence analysis. CDR sequences are nomenclature in the Kabat system or by the Chothia system (Kabat, EA et al., Sequences of Proteins of Immunological Interest, Fifth Edition, USD Department of Health and Human Services, US Government Printing Office (1991)), or by the Chothia system or by the Chothia system (Chothia & Lesk, Canonical Structures for the Hypervariable Regions of Immunoglobulins, J.Mol.Biol.196:901-917(1987) and / or the IMGT system or nomenclature (Dondelinger et al.,Understanding the Significance and Implications of Antibody Numbering and It can be defined using Antigen-Binding Surface / Residue Definition (Front Immunol, 9:2278 (2018)). The heavy chain contains HCDR1, HCDR2, and HCDR3. The light chain contains LCDR1, LCDR2, and LCDR3. The secretory form of the IgH C region of most antibodies consists of three C domains, CH1, CH2, CH3, and a hinge region, with the exception of Cμ, which contains a CH4 region and lacks a hinge region. The membrane-bound form of the IgH C region also has membrane and intracellular domains. The IgH constant region determines the isotype of the antibody, e.g., IgM, IgD, IgG1, IgG2, IgG3, IgG4, IgA, and IgE. It will be understood that non-human mammals encoding multiple Ig isotypes can undergo isotype class switching. There are two types of human IgL, Igκ and Igλ.
[0093] As used herein, the terms “monoclonal antibody” or “mAb” refer to antibodies produced by an identical set of immune cells, each being a clone of its own parent cell. Monoclonal antibodies have monovalent affinity (i.e., they bind to the same epitope).
[0094] As used herein, the term “antigen-binding fragment” refers to a polypeptide fragment comprising at least one CDR of an immunoglobulin heavy chain and / or immunoglobulin light chain that binds to amyloid-beta. In this regard, an antigen-binding fragment of an antibody may comprise one, two, three, four, five, or all six CDRs of the VH and VL sequences shown herein from an anti-amyloid-beta antibody described herein. In some embodiments, an antigen-binding fragment of an anti-amyloid-beta antibody comprises all six CDRs of the VH and VL sequences shown herein from an anti-amyloid-beta antibody disclosed herein. An antigen-binding fragment of an amyloid-beta-specific antibody described herein is capable of binding to amyloid-beta. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to amyloid-beta plaques, parenchymal amyloid, vascular amyloid, or diffuse amyloid-beta deposits.
[0095] In some embodiments, the antibodies and their antigen-binding fragments described herein each include sets of heavy and light chain CDRs, interposed between sets of heavy and light chain framework regions (FRs) that provide structural support to the CDRs and define the spatial relationships of the CDRs relative to each other. As used herein, the term “CDR set” refers to three hypervariable regions of the V region or V domain of the heavy or light chain. Starting from the N-terminus of the heavy or light chain, these regions are denoted “CDR1,” “CDR2,” and “CDR3,” respectively. Thus, the antigen-binding site includes six CDRs, each containing a set of CDRs from the V region or V domain of the heavy and light chains.
[0096] The "Fab" domain or fragment contains the N-terminal portion of IgH, including the V region and CH1 domain of IgH, as well as the entire IgL molecule. The "F(ab')2" domain contains the Fab domain and part of the hinge region, and the two IgH molecules are linked together via a disulfide bond within the intermediate hinge region. Both Fab and F(ab')2 are "antigen-binding fragments".
[0097] The crystallizable fragment of the antibody after papain digestion, containing the CH2 and CH3 domains, is referred to as the "Fc" domain, and the C-terminal portion of IgH is called the "Fc" domain. The Fc domain is the Ig portion that is recognized by cell receptors such as FcR and to which the complement-activating protein C1q binds. The lower hinge region encoded at the 5' portion of the CH2 exon provides flexibility within the antibody for binding to the FcR receptor. The boundary of the Fc domain may vary, but as specified herein. The human IgG heavy chain Fc domain, as defined, contains residue E216 at its carboxyl terminus of the CH3 domain (or CH4 domain for IgM and IgE antibodies), and its numbering is in the EU format described by Edelman. The term “Fc domain” may refer to this sequence as isolated, or to this sequence in the context of an antibody, antibody fragment, or Fc fusion protein. The amino acid sequences of Fc domains that do not exist in nature (also referred to herein as “variant Fc domains”) may contain one or more amino acid modifications. Polymorphisms have been observed at several Fc domain positions, including but not limited to positions 270, 272, 312, 315, 356, and 358, and therefore slight differences may exist between the presented sequence and sequences in the prior art.
[0098] The term "EU format as described by Edelman" refers to the residue numbering of human IgG1 EU antibodies as described by Edelman GM et al., (1969) Proc. Natl. Acad. USA, 63, 78-85. The residue numbering of human IgG2 and human IgG4 is also in the EU format (Dillon TM, et al.). See al., J Biol Chem. Jun 6;283(23):16206-15 (2008), Aalberse RC et al., Immunology 105:9-19 (2002), and Scholthauer T et al., Protein Engineering, Design and Selection, 29(10):457-466, (2016). Residue EU numbering can be determined by aligning the antibody in regions homologous to the antibody sequence with a "standard" EU numbered sequence.
[0099] The “Fv” fragment comprises a non-covalent VH::VL heterodimer containing an antigen-binding site. In certain embodiments, a single-stranded Fv (scFv) antibody is intended. scFv is a covalently bound VH::VL heterodimer expressed from a gene fusion containing genes encoding VH and VL linked by a peptide-encoding linker (e.g., Huston et al. (1988) Proc. Nat. Acad. Sci. USA 85(16):5879-5883, incorporated herein by reference). As used herein, the term “linker” refers to a polypeptide sequence that conjugates two or more antibody domains. The properties of linkers and their suitability for particular purposes are known in the art. For example, see Chen et al. Adv Drug Deliv Rev. October 15;65(10):1357-1369 (2013), incorporated herein by reference, which discloses various types of linkers, their properties, and related linker design tools and databases. Linkers can be flexible, rigid, or cleavable in vivo. Preferably, linkers are flexible. Flexible linkers typically contain small nonpolar (e.g., Gly) or polar (e.g., Ser or Thr) amino acids. The most commonly used flexible linkers have sequences consisting mainly of elongations of Gly and Ser residues ("GS" linkers). Optionally, flexible linkers contain repeats of five Gly and Ser residues.
[0100] When bispecific antibodies are used, they may be conventional bispecific antibodies prepared by various methods, for example, chemically or from hybrid hybridomas (see, for example, Holliger, P. and Winter G. Current Opinion Biotechnol. 4, 446-449 (1993)), or they may be any of the bispecific antibody fragments described above.
[0101] As used herein, the term “chimeric antibody” refers to an antibody encoded by a polynucleotide sequence containing polynucleotide sequences derived from two or more species, for example, human and mouse. As used herein, a chimeric antibody may also refer to an antibody containing regions derived from two or more different antibodies.
[0102] As used herein, the term “chimeric Ig chain” refers to an Ig heavy or Ig light chain encoded by a polynucleotide sequence comprising polynucleotide sequences derived from two or more species, e.g., human and mouse. For example, a chimeric Ig heavy chain may include a human VH domain, DH domain, JH domain, CH1 domain, and upper hinge region, as well as mouse CH2 and CH3 domains. In some embodiments, the intermediate hinge region is mouse. In some embodiments, the intermediate hinge region is human. In some embodiments, the intermediate hinge region is chimeric.
[0103] As used herein, “human antibody” refers to an antibody having a variable region and a constant region derived from a human germline immunoglobulin sequence. Humanized antibodies may contain amino acid residues not encoded by a human germline immunoglobulin sequence (e.g., mutations introduced by random or site-directed mutagenesis in vitro, or by somatic mutation in vivo). However, the term “human antibody” does not encompass antibodies (i.e., humanized antibodies) whose CDR sequence is derived from the germline of another mammalian species, such as mouse, and transplanted onto a human framework sequence. The term encompasses antibodies that have a sequence derived from human genes but have been modified, for example, to reduce potential immunogenicity, increase affinity, reduce effector function, or eliminate cysteine that may cause undesirable folding. The term also encompasses such antibodies that contain human amino acid sequences produced by recombination in non-human cells, which may confer a glycosylation pattern atypical to human cells.
[0104] As used herein, the terms “polypeptide,” “peptide,” or “protein” are used interchangeably to describe a chain of amino acids linked together by chemical bonds. Non-limiting examples of polypeptides or proteins include IgH, IgL, V domains, C domains, or antibodies.
[0105] As used herein, the term “amino acid modification” refers to at least one amino acid substitution, insertion, deletion, or mutation in an amino acid sequence compared to a wild-type amino acid sequence. Such modifications are within the ordinary skill of those skilled in the art. Several modifications, including amino acid deletions, substitutions, and additions to the Fc region, have been shown to alter the binding of the Fc domain to its ligand and / or receptor, resulting in simultaneous modification of effector function (e.g., Shields et al., J Biol Chem 276:6591-6604 (2001), Presta et al., Biochem Soc Trans 30:487-490 (2002), Escobar-Cabrera E et al. Antibodies. 6:7 (2017), Duncan AR et al. Nature. 1988; 332:738-740 (1988), Duncan AR et al. Nature. 332:563-564 (1988), Hezareh M et al. J Virol. 75:12161-12168 (2001), Oganesyan V et al. al.Acta Crystallogr D Biol Crystallogr;64:700-704(2008), Schlothauer T et al.Protein Eng Des Sel. Oct;29(10):457-466(2016), Tao MH et al. J. Immunol. 143:2595-2601 (1989), Von See Kreudenstein TS et al. MAbs. 5(5):646-654 (2013), Wang X et al. Protein Cell. 9(1):63-73 (2018), U.S. Patent Publications 2004 / 0132101, 2007 / 0111260, 2011 / 0287032, 2018 / 0194860, U.S. Patent No. 8409568, and International Publication WO2017 / 177337. Amino acid deletions are indicated by "Δ" and insertions by "In". For example, E216 Deletions of amino acid sequences up to E222 are indicated as ΔE216~E222. For example, the insertion of arginine (R) between amino acid residues 234 and 235 is indicated as InR234 / 235.
[0106] A "conservative amino acid substitution" is the replacement of an amino acid residue with a different amino acid residue that has similar biochemical properties (e.g., charge, hydrophobicity, or size). Generally, conservative amino acid substitutions do not substantially alter the functional properties of a protein. When comparing proteins containing conservative substitutions, the degree of sequence identity or similarity can be adjusted to account for the conservative nature of the substitutions. Such adjustments are well known in the art. See, for example, Pearson, Methods Mol. Biol. 243:307-31 (1994).
[0107] In the context of polypeptide (or polynucleotide) sequences, the term “sequence identity rate” is defined as the percentage of amino acid (or nucleic acid) residues in a candidate sequence that are identical to amino acid (or nucleic acid) residues in a reference polypeptide (or polynucleotide) sequence, after the sequences have been aligned and gaps have been introduced, if necessary, to achieve the maximum sequence identity rate, and no conservative substitutions are considered part of the sequence identity. Such conservative substitutions are taken into account when calculating the “sequence similarity rate” of the two sequences (in addition to identical residues). Similar but non-identical residue positions differ due to conservative amino acid substitutions.
[0108] Sequence alignment (for example, to determine amino acid sequence identity, sequence similarity, or sequence homology rate between a wild-type protein and a mutant protein) can be achieved in various ways within the scope of the skill of a person skilled in the art using publicly available sequence analysis computer software, such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), Gap, BESTFIT®, and other programs in the Wisconsin Package Version 10.0 or the Genetics Computer Group (GCG) (Madison, Wisconsin) software. A person skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment over the entire length of the sequences being compared. Polypeptide sequences can also be compared using FASTA with default or recommended parameters. In relation to polypeptide sequences, FASTA takes a query amino acid sequence and searches a sequence database using local sequence alignment to identify similar sequences within the database (each incorporated herein by reference (Pearson, Methods Enzymol. 183:63-98 (1990), Pearson, Methods Mol. Biol. 132:185-219 (2000), Pearson Curr Protoc Bioinformatics. Mar 24;53:3.9.1-25 (2016))). BLAST, using default parameters, in particular blastp or tblastn, can be used to compare query sequences with databases containing sequences from different biological sources. For example, Altschul et al., J. Mol. Biol. 215:403-410 (1990), Altschul et al., Nucleic Acids See Res.25:3389-402(1997) and Eser et al., PLoS One.22;9(12):e115445(2014).
[0109] Amino acids can be grouped based on their similar biochemical properties. Such groupings that can be used to define conservative substitutions include: 1) Amino acid residues with aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) Amino acid residues with aliphatic hydroxyl side chains: serine and threonine; 3) Amino acid residues with amide-containing side chains: asparagine and glutamine; 4) Amino acid residues with aromatic side chains : phenylalanine, tyrosine, and tryptophan; 5) Amino acid residues with basic side chains: lysine, arginine, and histidine; 6) Amino acid residues with acidic side chains: aspartic acid and glutamic acid; and 7) Amino acid residues with sulfuric acid-containing side chains: cysteine and methionine. Non-limiting examples of preferred conservative amino acid substituents include valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine.
[0110] The strength or affinity of an immunological binding interaction can be expressed in terms of the dissociation constant (K D ) of the interaction, and a smaller K D represents a greater affinity. The immunological binding properties of a selected polypeptide can be quantified using methods well known in the art. One such method involves measuring the rates of formation and dissociation of the antigen binding site / antigen complex, and these rates depend on the concentration of the complex partners, the affinity of the interaction, and geometric parameters that equally affect the rates in both directions. Therefore, the "on-rate constant" (K on ) and the "off-rate constant" (K off ) can both be determined by calculation of the concentration and the actual rates of association and dissociation. The ratio of K off / K on allows cancellation of all parameters not related to affinity, and is thus equal to the dissociation constant K D . See generally Davies et al. (1990) Annual Rev. Biochem. 59:439-473. An antibody has a KD A antibody is considered to bind specifically to an antigen when its concentration is ≤1 mM, preferably ≤100 nM. High affinity antibodies are generally low nanomolar (10 -9 ) K within the range D Antibodies with very high affinity generally have a picomolar (10) concentration. -12 ) K within the range D It has. K D The binding affinity constant can be measured by surface plasmon resonance using, for example, the BIACORE® system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). See also Jonsson et al., Ann. Biol. Clin. 51:19-26 (1993), Jonsson et al., Biotechniques 11:620-627 (1991), Jonsson et al., J. Mol. Recognit. 8:125-131 (1995), Johnsson et al., Anal. Biochem. 198:268-277 (1991), and Hearty S et al., Methods Mol Biol. 907:411-42 (2012), which are incorporated herein by reference. D It can also be measured using the KinExA® system (Sapidyne Instruments, Hanover, Germany and Boise, ID). An antibody, or its antigen-binding fragment, is said to "specifically bind," "immunologically bind," and / or "immunologically reactive" to amyloid beta if it reacts with amyloid beta at a detectable level (e.g., in an ELISA assay) and does not react detectably with unrelated polypeptides under similar conditions. In some embodiments, an anti-amyloid beta antibody or its antigen-binding fragment binds to amyloid beta plaques, parenchymal amyloid, vascular amyloid, or diffuse amyloid beta deposits.
[0111] "Pharmacologically acceptable" means that it is approved or eligible for approval by a federal or state regulatory body or a corresponding body in a country other than the United States, or that it is listed in the United States Pharmacopeia or any other generally recognized pharmacopoeia for use in animals, more specifically in humans.
[0112] "Pharmacologically acceptable salt" refers to a salt of the compound of the present invention that is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. Specifically, such salts are nontoxic and may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts may be (1) formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and equivalents, or with acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glyco Malic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoic acid)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-octo-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, triglycerides Examples of salts include acid addition salts formed with organic acids such as methylacetic acid, tertiary butylbutyrate, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and equivalents, or (2) salts formed when the acidic proton present in the parent compound is replaced by a metal ion, such as an alkali metal ion, an alkaline earth ion, or an aluminum ion, or cooperates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, and equivalents. Further examples of salts include, but only by example, salts of non-toxic organic or inorganic acids such as sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and equivalents, hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and equivalents, if the compound contains a basic functional group. The term "pharmaceutically acceptable cation" refers to an acceptable cation counterion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and equivalents. See, for example, Berge, et al., J. Pharm. Sci. (1977) 66(1):1-79.
[0113] As used herein, the term “administer” refers to any mode of transporting, delivering, introducing, or transporting the pharmaceutical compositions or other agents described herein. Such modes include, but are not limited to, oral administration, inhalation, topical contact, intravenous, intraperitoneal, intramuscular, intranasal, or subcutaneous administration.
[0114] As used herein, the term “unit dosage form” is defined to refer to the form in which the compounds disclosed herein are administered to a subject.
[0115] As used herein, the term "day" means a given continuous period of 24 hours.
[0116] The terms “subject,” “patient,” and “individual” are used interchangeably herein and include, but are not limited to, human and non-human animals, including mammals such as primates (e.g., crab-eating macaques, rhesus macaques), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the subject is a human ("human subject"). In certain embodiments, the human subject is an infant, child, or adolescent ("child subject"). In other embodiments, the human subject is a young adult, middle-aged adult, or elderly adult ("adult subject"). In certain embodiments, the subject is a non-human animal ("non-human subject").
[0117] The terms "disease," "disorder," "condition," and "illness" are used interchangeably herein. In some embodiments, the disease is Alzheimer's disease. In some embodiments, the disease is a cognitive impairment associated with Alzheimer's disease.
[0118] As used herein, and unless otherwise specified, the terms “to treat,” “to treat,” and “treatment” refer to measures taken while the subject is suffering from the specified disease, disorder, or condition, which reduce the severity of the disease, disorder, or condition, or slow or delay the progression of the disease, disorder, or condition (also known as “therapeutic measures”). The term refers to improving at least one symptom of the disease or disorder. To treat This includes curing, improving, or at least partially improving a disease or disorder, or any symptom thereof.
[0119] As used herein, the terms “prevent,” “prevent,” and “prevent” refer to the prevention or delay of recurrence or onset of coronavirus infection in a subject, or the reduction of one or more symptoms of coronavirus infection, as a result of administration of the compositions of this disclosure. For example, in the context of administering a treatment to a subject, “prevent,” “prevent,” and “prevent” refer to the inhibition, reduction, or delay of the onset of one or more symptoms associated with Alzheimer's disease, or the prevention or delay of recurrence, onset, or onset.
[0120] Generally, the “effective amount” of a compound refers to an amount sufficient to induce a desired biological response. As will be understood by those skilled in the art, the effective amount of the compound of the present invention may vary depending on the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and factors such as the age, weight, health, and condition of the subject.
[0121] As used herein, and unless otherwise specified, the “therapeutic dose” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, to delay or minimize one or more symptoms associated with the disease, disorder, or condition, or to improve cognitive function. The therapeutic dose of a compound means the amount of a therapeutic agent that provides a therapeutic benefit in the treatment of a disease, disorder, or condition, either alone or in combination with other therapies. The term “therapeutic dose” may include an amount that improves the overall treatment, reduces or avoids the symptoms or causes of the disease or condition, or enhances the therapeutic effect of another therapeutic agent.
[0122] The "therapeutic effective dose" refers to the effective amount in terms of dosage and duration required to achieve the desired preventive outcome. Typically, the prophylactic effective dose may be less than the therapeutic effective dose, as prophylactic doses are used in subjects before or in the early stages of disease.
[0123] In some embodiments, administration of the compounds described herein, or pharmaceutically acceptable salts thereof, improves cognitive function. In some embodiments, cognitive function refers to a set of mental tasks and functions, including, but not limited to, psychomotor performance, executive performance, emotion recognition, learning (e.g., visual, spatial), memory (e.g., semantics, episodic, procedural, priming, or work), orientation, language, problem-solving, visual perception, construction, and integration, planning, organizational skills, selective attention, inhibitory control, and the ability to mentally manipulate information. In some embodiments, cognitive function is one or more selected from the group consisting of psychomotor performance, executive performance, emotion recognition, learning (e.g., visual, spatial), memory (e.g., semantics, episodic, procedural, priming, or work), orientation, language, problem-solving, visual perception, construction, and integration, planning, organizational skills, selective attention, inhibitory control, and the ability to mentally manipulate information. In some embodiments, the compounds disclosed herein selectively target working memory and its improvement. In some embodiments, the compounds disclosed herein selectively target executive performance and its improvement. Scales of cognitive function include, for example, assessment tools designed to measure: (a) general intelligence, (b) nonverbal intelligence, (c) performance, (d) attention / executive function, (e) memory and learning, (f) visuomotor and motor function, and (g) language.
[0124] Any changes in cognitive function, for example, over time or through treatment, can be monitored by using one or more of these well-established tests at two or more points in time and comparing the results. The phrase “improve cognitive function,” as used herein, means improving the ability to perform symbolic operations, such as perceiving, remembering, creating mental images, having clarity of thought, being aware, reasoning, thinking, or judging an object. This refers to a favorable change. Favorable changes can be measured using any of the aforementioned tests on two or more occasions, for example, a first occasion to measure baseline cognitive function and a second occasion to measure cognitive function after a certain period (in which case treatment may have been administered). Such assessment tools are well known in the art and include, for example, the assessment tool described in Example 1 herein.
[0125] As used herein, the term “memory” is defined as the biological processes in the brain that enable the storage and retrieval of information.
[0126] As used herein, the term “working memory” is defined as a combination of brain processes that provide the temporary storage and manipulation of information necessary to perform complex cognitive tasks such as learning and reasoning.
[0127] As used herein, the term “learning” refers to the brain processes involved in acquiring skills, knowledge, and information.
[0128] As used interchangeably herein, the terms “executive function” or “executive performance” refer to a comprehensive term encompassing cognitive processes that modulate, control, and manage other cognitive processes, including planning, working memory, attention, problem-solving, verbal reasoning, inhibition, mental flexibility, task switching, and initiation and monitoring of behavior. The anterior frontal lobe region is necessary, but insufficient, for performing these functions.
[0129] When used in relation to working memory or executive function, “to improve,” “to make improvements,” or “improve,” or their grammatical variations, they refer to the ability to achieve a measurable improvement in performance related to a task used to test working memory or executive function in the subject.
[0130] As used herein, the term “pharmaceutically acceptable carrier” is used interchangeably and refers to any solvent, dispersion medium, coating, antimicrobial and antifungal agent, isotonic and absorption retardant, and equivalents, that are physiologically compatible. pharmaceutically acceptable carriers are well known in the art. See, for example, Remington's Pharmaceutical Sciences and USPharmacopeia: National Formulary, Mack Publishing Company, Easton, PA (1984), incorporated herein by reference. Some examples of pharmaceutically acceptable carriers are water, saline, phosphate-buffered saline, dextrose, glycerol, ethanol, and equivalents, and combinations thereof. Often, it is preferable to include isotonic agents, such as sugars, polyhydric alcohols, such as mannitol, sorbitol, or sodium chloride, in the composition. Additional examples of pharmaceutically acceptable carriers include humectants, or small amounts of auxiliary substances such as humectants or emulsifiers, preservatives, or buffers that enhance the shelf life or efficacy of the antibody. Pharmaceutical compositions may be prepared by mixing the compounds, antibodies, or antigen-binding fragments disclosed herein with acceptable carriers, excipients, or stabilizers in the form of, for example, lyophilized powders, slurries, aqueous solutions, or suspensions (for example, Hardman, et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharma See ceutical Dosage Forms: Tablets, Marcel Dekker, NY, Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY, Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, NY).
[0131] General This specification discloses pharmaceutical compositions, kits, and methods of treatment comprising (a) an NMDA receptor-positive allosteric regulator (NMDA PAM), (b) an anti-amyloid beta antibody or its antigen-binding fragment, and (c) a pharmaceutically acceptable carrier. This specification also discloses pharmaceutical compositions, kits, and methods of treatment comprising (a) a CYP46A1 inhibitor, (b) an anti-amyloid beta antibody or its antigen-binding fragment, and (c) a pharmaceutically acceptable carrier.
[0132] CYP46A1 inhibitors The CYP46A1 inhibitors useful in the compositions, kits, and methods of this disclosure are compounds that inhibit the enzyme cholesterol 24-hydroxylase (also known as CYP46A1 and CH24H), which converts cholesterol to 24S-hydroxycholesterol (24-HC) and, when administered in combination with an anti-amyloid-beta antibody or its antigen-binding fragment, exhibit beneficial effects for treating or preventing Alzheimer's disease as disclosed herein. CYP46A1 inhibitors are known to those skilled in the art. Therefore, any CYP46A1 inhibitor may be useful in the compositions, kits, and methods of this disclosure.
[0133] In some embodiments, the CYP46A1 inhibitors, each of which is incorporated herein by reference in whole, are any compounds disclosed in WO2020 / 243027, WO2013 / 054822, US9193709, WO2014 / 092100, US9643957, WO2014 / 163162, US9624184, WO2014 / 061676, US9296746, and WO2017 / 065287.
[0134] In some embodiments, the CYP46A1 inhibitor is selected from the group consisting of TAK-935, any of compounds A1 to A182, and pharmaceutically acceptable salts thereof. In some embodiments, the CYP46A1 inhibitor is any one of compounds A1 to A182 (see Table 1), or a pharmaceutically acceptable salt thereof. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13]
[0135] In some embodiments, the CYP46A1 inhibitor is any single compound shown in Table 1, or a pharmaceutically acceptable salt thereof.
[0136] The synthesis of Compounds A1 to A125 is described in WO2020 / 243027, and the synthesis of Compounds A126 to A182 is described in WO2022 / 115620. The disclosure of each of the aforementioned applications is incorporated herein by reference in its entirety.
[0137] NMDA receptor positive allosteric modulator NMDA PAMs useful in the compositions, kits and methods of the present disclosure are modulators of synaptic and / or extrasynaptic NMDA receptors, which, when administered in combination with an anti-amyloid beta antibody or an antigen-binding fragment thereof, are compounds that exhibit beneficial effects for treating or preventing Alzheimer's disease as disclosed herein. NMDA PAMs are known to those skilled in the art. Accordingly, any NDMA PAM may be useful in the compositions, kits, and methods of the present disclosure.
[0138] In some embodiments, the NDMA PAM is a neuroactive steroid. In some embodiments, the neuroactive steroid is any one of Compounds B1 to B543, or a pharmaceutically acceptable salt thereof. In some embodiments, the neuroactive steroid is any one of Compounds B1 to B543 (see Table 2): [Table 2-1] [Table 2-2] Table 2-3 Table 2-4 Table 2-5 Table 2-6 Table 2-7 Table 2-8 Table 2-9 Table 2-10 Table 2-11 Table 2-12 Table 2-13 Table 2-14 Table 2-15 Table 2-16 Table 2-17 Table 2-18 Table 2-19 Table 2-20 Table 2-21 Table 2-22 Table 2-23 Table 2-24 Table 2-25 Table 2-26 Table 2-27 Table 2-28 Table 2-29 Table 2-30 Table 2-31 Table 2-32 Table 2-33 Table 2-34 Table 2-35 Table 2-36 Table 2-37 Table 2-38 Table 2-39 Table 2-40 Table 2-41
[0139] In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B1 to B140 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B141 to B149 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B150 to B245 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B246 to B272 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B273 to B349 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B395 to B432 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B433 to B443 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B444 to B451 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B452 to B477 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B478 to B530 and their pharmaceutically acceptable salts. In some embodiments, the neuroactive steroid is selected from the group consisting of any one of compounds B531 to B543 and their pharmaceutically acceptable salts.
[0140] In some embodiments, the neuronal activity of any single compound or pharmaceutically acceptable salt thereof shown in Table 2.
[0141] The synthesis of compounds B1-B140 is described in WO2013 / 036835, the synthesis of B141-B149 is described in WO2015 / 195967, the synthesis of compounds B150-B245 is described in WO2014 / 160480, the synthesis of B246-B272 is described in WO2017 / 007832, the synthesis of B273-B394 is described in WO2017 / 007840, and the synthesis of B395-B432 is described in WO2017 / 007840. The combination of B433-B443 is described in WO2017 / 007836, the combination of B444-B451 is described in WO2017 / 193046, the combination of B452-B477 is described in WO2017 / 173358, the combination of B478-B530 is described in WO2018 / 075699, and the combination of B531-B543 is described in WO2018 / 064659. Each of the disclosures of the aforementioned applications is incorporated herein by reference in their entirety.
[0142] In some embodiments, NMDA PAM is 9-iodophenanthrene-3-carboxylic acid (UBP512), 6-(4-methylpentyl)naphthalene-2-carboxylic acid (UBP684), 4-cyclohexyl-N-(7-hydroxy-5-methyl-2-propyl[1,2,4]triazolo[1,5-a]pyrimidine-6-yl)benzenesulfonamide (GNE-9278), 2-butyl-7-(((ethyl(phenyl)amino)methyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidine-5-one (GNE-3476), 4-(4-hydroxy-1-(2-(6-methyl-1H-indole-3-yl)ethyl)-3-nicotinotinoyl-5-oxo-2,5-dihydro-1H-pyrrole-2-yl)benzoate methyl (PYD-111), 4-(3-acetyl-4-hydroxy-1-(2-(2-methyl-1H-indole-3-yl)ethyl)-5-oxo-2,5-dihydro-1H-pyrrole-2- The group consists of methyl benzoate (PYD-106), 3-chlorophenyl)(6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline-2(1H)-yl)methanone (CIQ), NYX-458, plazinemdor (5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidine-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidine-4-one), and pharmaceutically acceptable salts thereof. In some embodiments, NMDA PAM is BP512 or a pharmaceutically acceptable salt thereof. In some embodiments, NMDA PAM is UBP684 or a pharmaceutically acceptable salt thereof. In some embodiments, NMDA PAM is GNE-9278 or a pharmaceutically acceptable salt thereof. In some embodiments, NMDA PAM is GNE-3476 or a pharmaceutically acceptable salt thereof. In some embodiments, NMDA PAM is PYD-111 or a pharmaceutically acceptable salt thereof. In some embodiments, NMDA PAM is PYD-106 or a pharmaceutically acceptable salt thereof. In some embodiments, NMDA PAM is CIQ or a pharmaceutically acceptable salt thereof. In some embodiments, NMDA PAM is NYX-458 or a pharmaceutically acceptable salt thereof.In some embodiments, NMDA PAM is plazinemdor (5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidine-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidine-4-one) or a pharmaceutically acceptable salt thereof.
[0143] Anti-amyloid beta antibody The anti-amyloid-beta antibodies or their antigen-binding fragments useful in the compositions, kits, and methods of this disclosure are antibodies or their fragments that bind to amyloid-beta and, when administered in combination with an NMDA PAM or CYP inhibitor, exhibit beneficial effects for treating or preventing Alzheimer's disease as disclosed herein. Any anti-amyloid-beta antibodies or their antigen-binding fragments, including those disclosed in U.S. Patent Nos. 10,842,871, 10,131,708, 9,828,420, and 8,906,367, and U.S. Patent Publication No. 2015 / 013155267 (all of which are incorporated herein by reference), may be used in the pharmaceutical compositions, kits, and methods disclosed herein.
[0144] More specifically, the pharmaceutical compositions, kits, and methods disclosed herein include anti-amyloid-beta antibodies, antigen-binding fragments (or portions thereof), antibody light chains, antibody heavy chains, and fragments of these light or heavy chains. The anti-amyloid-beta antibodies and their antigen-binding fragments disclosed herein also include antibodies lacking a heavy chain signal sequence and / or a light chain signal sequence, as well as glycosylated antibodies. The anti-amyloid-beta antibodies and their antigen-binding fragments disclosed herein also include precursor antibodies, non-glycosylated antibodies, and antibodies in which the heavy chain and / or light chain contains a signal sequence.
[0145] The antibodies and their antigen-binding fragments described herein can be purified and / or isolated using known techniques. The "purified" or "isolated" antibodies or fragments are those of which the molecules of their origin (e.g., in a mixture such as cell supernatant or in a mixture of antibodies in a library) This includes antibodies that are at least partially isolated from a peptide (for example) and obtained by any other suitable method. Isolated antibodies include substantially pure (e.g., essentially pure) antibodies, as well as antibodies produced by chemical synthesis, recombinant techniques, and combinations thereof.
[0146] The anti-amyloid-beta antibody or its antigen-binding fragment may be human. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment of the Disclosure is chimeric. In some embodiments, the chimeric anti-amyloid-beta antibody or its antigen-binding fragment comprises a chimeric IgH chain and a human Igκ chain. In some embodiments, the chimeric anti-amyloid-beta antibody or its antigen-binding fragment comprises a chimeric IgH chain and a human Igλ chain. In some embodiments, the chimeric anti-S1 antibody comprises human and mouse sequences.
[0147] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises one to six complementarity-determining regions (CDRs) as disclosed herein.
[0148] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is selected from the group consisting of bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), aducanumab, and their antigen-binding fragments. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is bapinuzumab or its antigen-binding fragment. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is solanezumab or its antigen-binding fragment. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is gantenerumab or its antigen-binding fragment. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is crenezumab or its antigen-binding fragment. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is ponezumab or its antigen-binding fragment. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment is lecanemab (BAN2401) or its antigen-binding fragment. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment is aducanumab or its antigen-binding fragment.
[0149] In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which one of bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab binds. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which bapinuzumab binds. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which solanezumab binds. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which gantenerumab binds. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which crenezumab binds. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which ponezumab binds. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which lecanemab (BAN2401) binds. In some embodiments, an anti-amyloid-beta antibody or its antigen-binding fragment binds to the same structural epitope of amyloid-beta to which aducanumab binds.
[0150] In some embodiments, an anti-amyloid beta antibody or its antigen-binding fragment competes for the binding of one of the following to amyloid beta: bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab. Competitive inhibition. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment competitively inhibits the binding of bapinuzumab to amyloid-beta. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment competitively inhibits the binding of solanezumab to amyloid-beta. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment competitively inhibits the binding of gantenerumab to amyloid-beta. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment competitively inhibits the binding of ponezumab to amyloid-beta. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment competitively inhibits the binding of recanemab (BAN2401) to amyloid-beta. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment competitively inhibits the binding of aducanumab to amyloid-beta.
[0151] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of any one of the anti-amyloid-beta antibodies disclosed herein, as determined by Kabat, Chothia, or IMTG nomenclature. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of any one of bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), and aducanumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of bapinuzumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of solanezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of gantenerumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of crenezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of ponezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of lecanemab (BAN2401). In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises six CDRs of aducanumab.
[0152] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is (a) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 1, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 2, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 3, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 4, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 5, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 6, (b) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 11, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 12, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 13, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 14, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 15, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 16, (c) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 21, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 22, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 23, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 24, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 25, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 26, (d) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 31, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 32, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 34, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 36, (e) (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 41, (ii) SEQ ID NO: 42 A heavy chain variable domain (VH) comprising HCDR2 containing the amino acid sequence of (iii) SEQ ID NO: 43, and a light chain variable domain (VL) comprising LCDR1 containing the amino acid sequence of (i) SEQ ID NO: 44, (ii) LCDR2 containing the amino acid sequence of (ii) SEQ ID NO: 45, and (iii) LCDR3 containing the amino acid sequence of (iii) SEQ ID NO: 46. (f) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 51, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 52, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 53, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 54, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 55, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 56, or (g) A heavy chain variable domain (VH) comprising (i) HCDR1 containing the amino acid sequence of SEQ ID NO: 61, (ii) HCDR2 containing the amino acid sequence of SEQ ID NO: 62, and (iii) HCDR3 containing the amino acid sequence of SEQ ID NO: 63, and a light chain variable domain (VL) comprising (i) LCDR1 containing the amino acid sequence of SEQ ID NO: 64, (ii) LCDR2 containing the amino acid sequence of SEQ ID NO: 65, and (iii) LCDR3 containing the amino acid sequence of SEQ ID NO: 66.
[0153] In some embodiments, an anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) comprising (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) an HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and (iii) an HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable domain (VL) comprising (b) an LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, (ii) an LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and (iii) an LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.
[0154] In some embodiments, an anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) comprising (a) (i) HCDR1 comprising the amino acid sequence of SEQ ID NO: 11, (ii) HCDR2 comprising the amino acid sequence of SEQ ID NO: 12, and (iii) HCDR3 comprising the amino acid sequence of SEQ ID NO: 13, and a light chain variable domain (VL) comprising (i) LCDR1 comprising the amino acid sequence of SEQ ID NO: 14, (ii) LCDR2 comprising the amino acid sequence of SEQ ID NO: 15, and (iii) LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.
[0155] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) comprising (a) (i) HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, (ii) HCDR2 comprising the amino acid sequence of SEQ ID NO: 22, and (iii) HCDR3 comprising the amino acid sequence of SEQ ID NO: 23, and a light chain variable domain (VL) comprising (b) (i) LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, (ii) LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and (iii) LCDR3 comprising the amino acid sequence of SEQ ID NO: 26.
[0156] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) comprising (a) (i) HCDR1 comprising the amino acid sequence of SEQ ID NO: 31, (ii) HCDR2 comprising the amino acid sequence of SEQ ID NO: 32, and (iii) HCDR3 comprising the amino acid sequence of SEQ ID NO: 33, and a light chain variable domain (VL) comprising (b) (i) LCDR1 comprising the amino acid sequence of SEQ ID NO: 34, (ii) LCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and (iii) LCDR3 comprising the amino acid sequence of SEQ ID NO: 36.
[0157] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) comprising (a) (i) HCDR1 comprising the amino acid sequence of SEQ ID NO: 41, (ii) HCDR2 comprising the amino acid sequence of SEQ ID NO: 42, and (iii) HCDR3 comprising the amino acid sequence of SEQ ID NO: 43, and (b) (i) LCDR1 comprising the amino acid sequence of SEQ ID NO: 44, (ii) LCDR2 comprising the amino acid sequence of SEQ ID NO: 45, and (iii) sequence number It contains a light chain variable domain (VL) containing LCDR3 with amino acid sequence number 46.
[0158] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) comprising (a) (i) HCDR1 comprising the amino acid sequence of SEQ ID NO: 51, (ii) HCDR2 comprising the amino acid sequence of SEQ ID NO: 52, and (iii) HCDR3 comprising the amino acid sequence of SEQ ID NO: 53, and a light chain variable domain (VL) comprising (b) (i) LCDR1 comprising the amino acid sequence of SEQ ID NO: 54, (ii) LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, and (iii) LCDR3 comprising the amino acid sequence of SEQ ID NO: 56.
[0159] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) comprising (a) (i) HCDR1 comprising the amino acid sequence of SEQ ID NO: 61, (ii) HCDR2 comprising the amino acid sequence of SEQ ID NO: 62, and (iii) HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and a light chain variable domain (VL) comprising (b) (i) LCDR1 comprising the amino acid sequence of SEQ ID NO: 64, (ii) LCDR2 comprising the amino acid sequence of SEQ ID NO: 65, and (iii) LCDR3 comprising the amino acid sequence of SEQ ID NO: 66.
[0160] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises a heavy chain variable domain (VH) and / or light chain variable domain (VL) domain of any one of the anti-amyloid-beta antibodies disclosed herein. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises a VH domain of any one of bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab.
[0161] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VH domain of one of the following: bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VH domain of bapinuzumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VH domain of solanezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VH domain of gantenerumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VH domain of crenezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VH domain of ponezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the VH domain of lecanemab (BAN2401). In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the VH domain of aducanumab.
[0162] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VL domain of one of the following: bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VL domain of bapinuzumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VL domain of solanezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VL domain of gantenerumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VL domain of crenezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment contains the VL domain of ponezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the VL domain of lecanemab (BAN2401). In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the VL domain of aducanumab.
[0163] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the VH domain and VL domain of one of the following: bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the VH domain and VL domain of bapinuzumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the VH domain and VL domain of solanezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the VH domain and VL domain of gantenerumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the VH domain and VL domain of crenezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the VH domain and VL domain of ponezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the VH and VL domains of lecanemab (BAN2401). In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the VH and VL domains of aducanumab.
[0164] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) comprising (a) the amino acid sequence of SEQ ID NO: 7, (b) the amino acid sequence of SEQ ID NO: 17, (c) the amino acid sequence of SEQ ID NO: 27, (d) the amino acid sequence of SEQ ID NO: 37, (e) the amino acid sequence of SEQ ID NO: 47, (f) the amino acid sequence of SEQ ID NO: 57, or (g) the amino acid sequence of SEQ ID NO: 67.
[0165] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) comprising (a) the amino acid sequence of SEQ ID NO: 8, (b) the amino acid sequence of SEQ ID NO: 18, (c) the amino acid sequence of SEQ ID NO: 28, (d) the amino acid sequence of SEQ ID NO: 38, (e) the amino acid sequence of SEQ ID NO: 48, (f) the amino acid sequence of SEQ ID NO: 58, or (g) the amino acid sequence of SEQ ID NO: 68.
[0166] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 7. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 7, and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 8.
[0167] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 17. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 18. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 17, and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 18.
[0168] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 28. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 27, and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 28.
[0169] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is the SEQ ID NO. It includes a heavy chain variable domain (VH) containing the amino acid sequence of 37. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 38. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 37, and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 38.
[0170] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 47. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 48. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 47, and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 48.
[0171] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 57. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 57, and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 58.
[0172] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 67. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 68. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 67, and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 68.
[0173] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the heavy and / or light chain of any one of the anti-amyloid-beta antibodies disclosed herein.
[0174] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain from one of the following: bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain from bapinuzumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain from solanezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain from gantenerumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain from crenezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain from ponezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises a heavy chain from lecanemab (BAN2401). In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the heavy chain of aducanumab.
[0175] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the light chain of one of the following: bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the light chain of bapinuzumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the light chain of solanezumab. The light chain is included. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment includes the light chain of gantenerumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment includes the light chain of crenezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment includes the light chain of ponezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment includes the light chain of lecanemab (BAN2401). In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment includes the light chain of aducanumab.
[0176] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the heavy and light chains of one of the following: bapinuzumab, solanezumab, gantenerumab, crenezumab, ponezumab, lecanemab (BAN2401), or aducanumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the heavy and light chains of bapinuzumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the heavy and light chains of solanezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the heavy and light chains of gantenerumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the heavy and light chain domains of crenezumab. In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment comprises the heavy and light chain domains of ponezumab. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the heavy and light chains of lecanemab (BAN2401). In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment comprises the heavy and light chain domains of aducanumab.
[0177] In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-amyloid-beta antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 9 and a light chain containing the amino acid sequence of SEQ ID NO: 10.
[0178] In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 19. In some embodiments, the anti-amyloid-beta antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 20. In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 19 and a light chain containing the amino acid sequence of SEQ ID NO: 20.
[0179] In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 29. In some embodiments, the anti-amyloid-beta antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 30. In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 29 and a light chain containing the amino acid sequence of SEQ ID NO: 30.
[0180] In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 39. In some embodiments, the anti-amyloid-beta antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 40. In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 39 and a light chain containing the amino acid sequence of SEQ ID NO: 40.
[0181] In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 49. In some embodiments, the anti-amyloid-beta antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 50. In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 49 and a light chain containing the amino acid sequence of SEQ ID NO: 50. include.
[0182] In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-amyloid-beta antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 59 and a light chain containing the amino acid sequence of SEQ ID NO: 60.
[0183] In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 69. In some embodiments, the anti-amyloid-beta antibody comprises a light chain containing the amino acid sequence of SEQ ID NO: 70. In some embodiments, the anti-amyloid-beta antibody comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 69 and a light chain containing the amino acid sequence of SEQ ID NO: 70.
[0184] Anti-amyloid-beta antibodies or their antigen-binding fragments may contain one of the complementarity-determining regions (CDRs) (i.e., HCDRs, LCDRs), VH, VL, heavy chain sequences, or light chain sequences shown in Tables 3-9. Tables 3-9 provide details of VH, VL, and various anti-amyloid-beta antibodies. [Table 3] [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9]
[0185] In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a constant domain of human IgG1, IgG2, IgG3, or IgG4. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a human IgG1 constant region. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a human IgG2 constant region. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a human IgG3 constant region. In some embodiments, the anti-amyloid-beta antibody or its antigen-binding fragment includes a human IgG4 constant region.
[0186] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is a human anti-amyloid beta antibody or its antigen-binding fragment.
[0187] In some embodiments, the antigen-binding fragment is a single-chain antibody, Fv, Fab, Fab', F(ab')2, Fd, a single-chain Fv molecule (scFv), a bispecific single-chain Fv dimer, a diabody, a domain deletion antibody, or a single-domain antibody (dAb). In some embodiments, the anti-amyloid beta antibody is a whole antibody. In some embodiments, the anti-amyloid beta antibody is a whole antibody. Amyloid-beta antibodies are single-chain antibodies. In some embodiments, the anti-amyloid-beta antibody is scFv. In some embodiments, the anti-amyloid-beta antibody is Fab. In some embodiments, the anti-amyloid-beta antibody is F(ab')2. In some embodiments, the anti-amyloid-beta antibody is Fv. In some embodiments, the anti-amyloid-beta antibody is Fd. In some embodiments, the anti-amyloid-beta antibody is a bispecific single-chain Fv dimer. In some embodiments, the anti-amyloid-beta antibody is a diabody. In some embodiments, the anti-amyloid-beta antibody is a single-domain antibody (dAb). In some embodiments, the anti-amyloid-beta antibody is a bispecific antibody.
[0188] In some embodiments, the anti-amyloid beta antibody or its antigen-binding fragment is human. In some embodiments, the human anti-amyloid beta or its antigen-binding fragment comprises a human IgH chain and a human Igκ chain. In some embodiments, the human anti-amyloid beta or its antigen-binding fragment comprises a human IgH chain and a human Igλ chain. In some embodiments, the isotype of the anti-amyloid beta antibody is selected from IgM, IgD, IgG (such as IgG1, IgG2, IgG3, and IgG4), IgA, and IgE. In some embodiments, the isotype of the anti-amyloid beta antibody is selected from IgG1, IgG2, IgG3, and IgG4.
[0189] In some embodiments, the anti-amyloid-beta antibody binds to an Fc receptor (FcR) selected from FcγR, FcεR, and FcαR. In some embodiments, the anti-amyloid-beta antibody binds to an FcγR selected from FcγRI(CD64), FcγRII(CD32), and FcγRIII(CD16), including its isoform. In some embodiments, the Fc region of the anti-amyloid-beta antibody contains mutations to preferentially bind to a particular FcγR.
[0190] In some embodiments, an anti-amyloid beta antibody or its antigen-binding fragment binds to amyloid beta plaques, parenchymal amyloid, vascular amyloid, or diffuse amyloid beta deposits.
[0191] Pharmaceutical composition In one embodiment, the present disclosure provides a pharmaceutical composition comprising compound 1 or a pharmaceutically acceptable salt thereof (also referred to as the “active ingredient”) and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises an effective amount of compound 1 or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises a therapeutically effective amount of compound 1 or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises a prophylactically effective amount of compound 1 or a pharmaceutically acceptable salt thereof.
[0192] In some embodiments, the pharmaceutical composition contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the pharmaceutical composition contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the pharmaceutical composition contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.5 mg of compound 1. In some embodiments, the pharmaceutical composition contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1.
[0193] In some embodiments, the pharmaceutical composition contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 1.0 mg of compound 1. In some embodiments, the pharmaceutical composition contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the pharmaceutical composition, The composition contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.5 mg of compound 1. In some embodiments, the pharmaceutical composition contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the pharmaceutical composition contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 1.0 mg of compound 1. In some embodiments, the pharmaceutical composition contains 1.0 mg of a pharmaceutically acceptable salt of compound 1.
[0194] In one embodiment, a pharmaceutical composition is provided herein comprising (a) an NMDA receptor-positive allosteric modulator, (b) an anti-amyloid beta antibody or its antigen-binding fragment, and (c) a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises (a) an effective amount of an NMDA receptor-positive allosteric modulator, (b) an effective amount of anti-amyloid beta or its antigen-binding fragment, and (c) a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises (a) a therapeutically effective amount of an NMDA receptor-positive allosteric modulator, (b) a therapeutically effective amount of anti-amyloid beta or its antigen-binding fragment, and (c) a pharmaceutically acceptable carrier.
[0195] In one embodiment, a pharmaceutical composition is provided herein comprising (a) a CYP46A1 inhibitor, (b) an anti-amyloid beta antibody or its antigen-binding fragment, and (c) a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises (a) an effective amount of CYP46A1, (b) an effective amount of anti-amyloid beta or its antigen-binding fragment, and (c) a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises (a) a therapeutically effective amount of CYP46A1, (b) a therapeutically effective amount of anti-amyloid beta or its antigen-binding fragment, and (c) a pharmaceutically acceptable carrier.
[0196] The pharmaceutical compositions provided herein may be administered by various routes, including, but not limited to, oral (enteral), parenteral (by injection), rectal, transdermal, intradermal, intrathecal, subcutaneous (SC), intravenous (IV), intramuscular (IM), and intranasal. In some embodiments, the compound or pharmaceutical composition is administered orally to the subject. In some embodiments, the compound or pharmaceutical composition is administered parenterally to the subject. In some embodiments, the compound or pharmaceutical composition is administered rectally to the subject. In some embodiments, the compound or pharmaceutical composition is administered transdermally to the subject. In some embodiments, the compound or pharmaceutical composition is administered intradermally to the subject. In some embodiments, the compound or pharmaceutical composition is administered intrathecally to the subject. In some embodiments, the compound or pharmaceutical composition is administered subcutaneously to the subject. In some embodiments, the compound or pharmaceutical composition is administered intravenously to the subject. In some embodiments, the compound or pharmaceutical composition is administered intramuscularly to the subject. In some embodiments, the compound or pharmaceutical composition is administered intranasally to the subject.
[0197] In general, the compounds provided herein (i.e., Compound 1, the CYP46A1 inhibitor, NMDA PAM, and anti-amyloid beta or its antigen-binding fragment) are administered in effective doses. The actual amount of compound administered will typically be determined by a physician in light of the relevant circumstances, including the condition being treated, the chosen route of administration, the actual compound administered, the individual patient's age, weight, and response, the severity of the patient's symptoms, and their equivalents.
[0198] The pharmaceutical compositions of the present invention may be further delivered using various administration methods. For example, in certain embodiments, the pharmaceutical composition may be given as a bolus to raise the concentration of the compound in the blood to an effective level. The arrangement of bolus doses depends on the systemic level of the desired active ingredient throughout the body. For example, intramuscular or subcutaneous bolus doses allow for the slow release of the active ingredient, while boluses delivered directly to a vein (e.g., via IV infusion) rapidly raise the concentration of the active ingredient in the blood to an effective level. This allows for much faster delivery. In other embodiments, the pharmaceutical composition may be administered as a continuous infusion, for example, by IV drip, to provide maintenance of a steady-state concentration of the active ingredient in the body of the subject. Furthermore, in yet another embodiment, the pharmaceutical composition may be administered first as a bolus dose, followed by continuous infusion.
[0199] Compositions for oral administration may take the form of a bulk liquid solution or suspension, or a bulk powder. However, more generally, compositions are presented in unit dosage forms to facilitate precise administration. The term "unit dosage form" refers to a physically distinct unit suitable as a unit dosage form for human subjects and other mammals, each unit containing a predetermined amount of the active substance calculated to produce the desired therapeutic effect in conjunction with suitable pharmaceutically acceptable excipients. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or, in the case of solid compositions, pills, tablets, capsules, and equivalents. In such compositions, the compound is usually a minor component (about 0.1 to about 50% by weight, preferably about 1 to about 40% by weight), with the remainder being various vehicles or excipients and processing aids that help form the desired dosage form. The above-mentioned components of orally administered, injectable, or topically administered compositions are merely representative. Other materials, as well as processing techniques and equivalents, are described by reference in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania.
[0200] The composition may be in a sustained-release form or derived from a sustained-release drug delivery system. A typical description of sustained-release materials can be found in Remington's Pharmaceutical Sciences.
[0201] The present invention also relates to pharmaceutically acceptable acid addition salts of the compounds of the present disclosure (i.e., Compound 1, the CYP46A1 inhibitor, and NMDA PAM). Acids that can be used to prepare pharmaceutically acceptable salts form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions such as hydrochloride, hydroiodide, hydrobromide, nitrate, sulfate, bisulfate, phosphate, acetate, lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate, p-toluenesulfonate, and equivalents.
[0202] When used to prevent the development of CNS disorders, the compounds provided herein would typically be administered to subjects at risk of developing the condition, at the dosage levels described herein, under the advice and supervision of a physician. Subjects at risk of developing a particular condition generally include subjects with a family history of the condition, or subjects identified as particularly susceptible to the condition through genetic testing or screening.
[0203] kit In one embodiment, a kit is provided herein comprising a composition comprising an NMDA receptor-positive allosteric modulator as disclosed herein, a composition comprising an anti-amyloid-beta antibody or its antigen-binding fragment as disclosed herein, and a package insert. In some embodiments, a kit is provided herein comprising a first container, a second container, and a package insert, wherein the first container comprises a composition comprising an NMDA receptor-positive allosteric modulator as disclosed herein, the second container comprises a composition comprising an anti-amyloid-beta antibody or its antigen-binding fragment as disclosed herein, and the package insert comprises instructions for treating Alzheimer's disease in a subject. The kit may comprise one distinctly different composition or two or more distinctly different compositions, and it is understood that the first composition comprises an NMDA PAM, and the second composition comprises an anti-amyloid-beta antibody or its antigen-binding fragment.
[0204] It is understood that the NMDA PAM composition and the anti-amyloid-beta antibody or its antigen-binding fragment composition may independently have any dosage form. For example, the anti-amyloid-beta antibody or its antigen-binding fragment composition may be in liquid form, while the NMDA PAM composition may be in solid form.
[0205] In one embodiment, a kit is provided herein comprising a composition comprising a CYP46A1 inhibitor disclosed herein, a composition comprising an anti-amyloid-beta antibody or its antigen-binding fragment disclosed herein, and a package insert. In some embodiments, a kit is provided herein comprising a first container, a second container, and a package insert, wherein the first container comprises a composition comprising a CYP46A1 inhibitor disclosed herein, the second container comprises a composition comprising an anti-amyloid-beta antibody or its antigen-binding fragment disclosed herein, and the package insert comprises instructions for treating Alzheimer's disease in a subject. The kit may comprise one distinctly different composition or two or more distinctly different compositions, and it is understood that the first composition comprises a CYP46A1 inhibitor, and the second composition comprises an anti-amyloid-beta antibody or its antigen-binding fragment.
[0206] It is understood that the CYP46A1 inhibitor composition and the anti-amyloid beta antibody or its antigen-binding fragment composition may independently have any dosage form. For example, the anti-amyloid beta antibody or its antigen-binding fragment composition may be in liquid form, while the CYP46A1 inhibitor composition may be in solid form.
[0207] It is understood that the accompanying documentation includes instructions for treating any of the conditions disclosed herein. In some embodiments, the instructions are for treating Alzheimer's disease. In some embodiments, the instructions are for preventing Alzheimer's disease. In some embodiments, the instructions are for treating cognitive impairment in subjects with Alzheimer's disease. In some embodiments, the instructions are for preventing Alzheimer's disease. In some embodiments, the instructions are for preventing cognitive impairment in subjects with Alzheimer's disease. In some embodiments, the instructions are for treating cognitive impairment caused by Alzheimer's disease in subjects. In some embodiments, the instructions are for preventing cognitive impairment caused by Alzheimer's disease in subjects. In some embodiments, the instructions are for treating mild cognitive impairment caused by Alzheimer's disease in subjects. In some embodiments, the instructions are for preventing mild cognitive impairment caused by Alzheimer's disease in subjects. In some embodiments, the instructions are for improving cognition in subjects with Alzheimer's disease. In some embodiments, the instructions are for slowing cognitive decline caused by Alzheimer's disease in subjects. In some embodiments, the instructions are for reducing amyloid-beta plaques in the brains of subjects with Alzheimer's disease. In some embodiments, the instructions are for reducing the deposition of amyloid-beta plaques in the brains of subjects with Alzheimer's disease. In some embodiments, the instructions are for treating mild cognitive impairment (MCI) associated with Alzheimer's disease. In some embodiments, the instructions are for improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. In some embodiments, the instructions are for improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. In some embodiments, the instructions are for improving learning in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease.In some embodiments, the instructions are for improving learning and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. In some embodiments, the instructions are for treating mild dementia associated with Alzheimer's disease in subjects. In some embodiments, the instructions are for Alzheimer's disease. The purpose is to improve executive function in subjects with related mild cognitive impairment. In some embodiments, the commands are for improving working memory in subjects with Alzheimer's disease-related mild cognitive impairment. In some embodiments, the commands are for improving learning in subjects with Alzheimer's disease-related mild cognitive impairment. In some embodiments, the commands are for improving learning and working memory in subjects with Alzheimer's disease-related mild cognitive impairment.
[0208] In some embodiments, the kit includes instructions for simultaneously administering an anti-amyloid-beta antibody or its antigen-binding fragment and NMDA PAM. In some embodiments, the kit includes instructions for sequentially administering an anti-amyloid-beta antibody or its antigen-binding fragment and NMDA PAM. In some embodiments, the kit includes instructions for separately administering an anti-amyloid-beta antibody or its antigen-binding fragment and NMDA PAM. In some embodiments, the kit includes instructions for administering an anti-amyloid-beta antibody or its antigen-binding fragment before NMDA PAM. In some embodiments, the kit includes instructions for administering an anti-amyloid-beta antibody or its antigen-binding fragment before NMDA PAM. In some embodiments, the kit includes instructions for administering an anti-amyloid-beta antibody or its antigen-binding fragment and NMDA PAM at the same frequency. In some embodiments, the kit includes instructions for administering an anti-amyloid-beta antibody or its antigen-binding fragment and NMDA PAM at different frequencies. Includes instructions for administering PAM.
[0209] In some embodiments, the kit includes instructions for simultaneously administering an anti-amyloid beta antibody or its antigen-binding fragment and a CYP46A1 inhibitor. In some embodiments, the kit includes instructions for sequentially administering an anti-amyloid beta antibody or its antigen-binding fragment and a CYP46A1 inhibitor. In some embodiments, the kit includes instructions for separately administering an anti-amyloid beta antibody or its antigen-binding fragment and a CYP46A1 inhibitor. In some embodiments, the kit includes instructions for administering an anti-amyloid beta antibody or its antigen-binding fragment before a CYP46A1 inhibitor. In some embodiments, the kit includes instructions for administering an anti-amyloid beta antibody or its antigen-binding fragment before a CYP46A1 inhibitor. In some embodiments, the kit includes instructions for administering an anti-amyloid beta antibody or its antigen-binding fragment and a CYP46A1 inhibitor at the same frequency. In some embodiments, the kit includes instructions for administering an anti-amyloid beta antibody or its antigen-binding fragment and a CYP46A1 inhibitor at different frequencies.
[0210] The kits of this disclosure may be in any suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, ampoules, jars, syringes, flexible packaging (e.g., sealed Mylar or plastic bags), and equivalents. The kits may optionally provide additional components such as buffers and interpretive information.
[0211] The first and second containers may be the same or different in shape (e.g., vials, syringes, and bottles) and / or made of the same or different materials (e.g., plastic or glass). The kit may further include other materials that may be useful for administering the drug, such as diluents, filters, IV bags and lines, needles and syringes.
[0212] In some embodiments, the present invention provides a manufactured article comprising the contents of a kit described herein.
[0213] Treatment and Usage Methods The compounds, pharmaceutical compositions, and kits disclosed herein are useful for treating or preventing Alzheimer's disease.
[0214] Alzheimer's disease (AD) is a type of dementia primarily identified by clinical diagnosis and established by disease markers. It is a continuum with certain operationally defined stages of disease progression. AD pathology begins before the onset of clinical symptoms. For example, amyloid plaques, one marker of AD pathology, form 10–20 years before the onset of AD dementia. The currently recognized stages of AD include preclinical, prodromal, mild, moderate, and severe. These stages can be further subdivided based on the severity of symptoms and the progression of AD.
[0215] Those skilled in the art will recognize that differences between patient groups may not be clearly distinct in a particular clinical setting. Nevertheless, clinical disease stages can be characterized by measuring various characteristics or markers, as well as changes in these characteristics or markers over time, such as amyloid-beta accumulation (CSF / PET), synaptic dysfunction (FDG-PET / fMRI), tau-mediated nerve injury (CSF), brain structure (volumetric MRI), cognition, and clinical function. Clifford Jack et al. Lancet. Neurol. 2010 January;9(1):119.
[0216] NINCDS-ADRDA Criteria (McKhann GM, V. diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Inst.on The current central clinical criteria for all dementias, referred to as the Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (Alzheimer's & Dementia 7(2011)263-269), are publicly known in the art and can be adopted in practicing this invention. These include cognitive or behavioral impairments, including a decline in the ability to acquire and remember new information, a decline in reasoning and handling complex tasks, a decline in visuospatial abilities, a decline in language function (speaking, reading, writing), and changes in personality, behavior, or attitude. Id. Alzheimer's disease is currently diagnosed using the central criteria and is typically characterized by a gradual onset of symptoms over months to years, rather than a sudden onset over hours or days. Subjects with Alzheimer's disease usually have a clear medical history of reported or observed cognitive deterioration. As new information on Id. AD becomes available, other diagnostic classification systems have evolved. These systems include the new research criteria of the International Working Group (IWG) for the diagnosis of Alzheimer's disease (Dubois B et al. Lancet). These include the criteria for Neurol 2007;6(8):734-736, the IWG study criteria (Dubois et al. Lancet Neurol 2010;9(11):1118-27), the NIA / AA criteria (Jack CR et al. Alzheimer's Dement 2011;7(3):257-62), and the DSM-5 criteria (American Psychiatric Association, DSM-5, 2013). These classification systems can also be employed when diagnosing AD subjects for treatment by the methods of the present invention.
[0217] Subjects with Alzheimer's disease as referred to in the methods herein include, but are not limited to, patients with preclinical, prodromal, mild, moderate, or severe Alzheimer's disease.
[0218] Patients with Alzheimer's disease requiring treatment range from those with amyloid pathology and early neurodegeneration to those with progressive cognitive impairment, widespread neurodegeneration and irreversible neuronal loss accompanied by functional impairment, and those with dementia. Patients with preclinical Alzheimer's disease can be identified by the asymptomatic stage (with or without memory complaints) and the emergence of newly appearing episodic memory and executive function deficits. This stage is typically associated with Alzheimer's disease. It is characterized by the appearance of in vivo molecular biomarkers for the disease and the absence of clinical symptoms.
[0219] Pre-Alzheimer's disease patients are in a pre-dementia stage characterized primarily by cognitive impairment and newly emerging functional impairments accompanied by disease progression. Pre-AD patients typically have an MMSE score of 24–30 (inclusive), spontaneous memory complaints, objective memory loss defined as a free recall score of ≤27 on the FCSRT, a global CDR score of 0.5, the absence of significant levels of impairment in other cognitive domains, and essentially preserved activities of daily living, as well as the absence of dementia.
[0220] Patients with mild Alzheimer's disease (AD) typically have an MMSE score of 20–26 (comprehensive), a global CDR of 0.5 or 1.0, and meet the National Institute on Aging-Alzheimer's Association's central clinical criteria for likely AD (see Section 22).
[0221] Based on clinical symptoms, a diagnosis of Alzheimer's disease (AD) indicates that patients with mild AD may exhibit marked behavior in the workplace, forgetfulness, mood swings, and attention deficits. Patients with moderate AD may exhibit cognitive impairment, limited daily activities, disorientation, asthenia, agnosia, aphasia, and behavioral abnormalities. Patients with severe AD are characterized by loss of independence, impaired memory and speech, and incontinence.
[0222] In some embodiments, this disclosure is, 18The present invention provides treatment for early-stage patients who are amyloid-positive, as assessed by F-AV-45 PET scans. Patients may be asymptomatic or exhibit only transient symptoms of headache, confusion, difficulty walking, or visual impairment. Patients may or may not be ApoE4 carriers, as determined by ApoE genotyping. In other embodiments, the present invention provides treatment for patients with any medical or neurological condition (other than AD) that may be contributing to cognitive impairment of the subject, such as stroke or other cerebrovascular disease, other neurodegenerative diseases, a history of clinically significant psychiatric disorder, acute or subacute minor or major hemorrhage, previous major hemorrhage, or superficial iron deposition disease, but even these patients may be treated after screening and selection by a qualified clinician.
[0223] Therefore, in one embodiment, a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject, wherein the subject is given compound 1 [ka] Methods comprising administering compound 1 or a pharmaceutically acceptable salt thereof are provided herein. In some embodiments, a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, A pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0224] In one embodiment, a method for treating mild dementia associated with Alzheimer's disease in a subject is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for treating mild dementia associated with Alzheimer's disease in a subject is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for treating mild dementia associated with Alzheimer's disease in a subject is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0225] In another embodiment, a method for treating mild cognitive impairment (MCI) caused by Alzheimer's disease in a subject is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for treating mild cognitive impairment (MCI) caused by Alzheimer's disease in a subject is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for treating mild cognitive impairment (MCI) caused by Alzheimer's disease in a subject is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. It is administered. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0226] In another embodiment, a method for treating mild dementia caused by Alzheimer's disease in a subject is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for treating mild dementia caused by Alzheimer's disease in a subject is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for treating mild dementia caused by Alzheimer's disease in a subject is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0227] In another embodiment, a method for treating mild cognitive impairment (MCI) in a subject having Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for treating mild cognitive impairment (MCI) in a subject having Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for treating mild cognitive impairment (MCI) in a subject having Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0228] In another embodiment, a method for treating mild cognitive impairment in a subject having Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for treating mild cognitive impairment in a subject having Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for treating mild cognitive impairment in a subject having Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0229] In one embodiment, a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is , administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0230] In one embodiment, a method for improving executive function in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving executive function in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving executive function in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0231] In another embodiment, a method for improving executive function in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving executive function in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving executive function in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. Methods comprising administering are provided herein. In some embodiments, compound 1 is administered to a subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to a subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a subject at a dose of about 3 mg / day. In some embodiments, compound 1 is administered to a subject at a dose of about 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to a subject at a dose of about 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0232] In another embodiment, a method for improving executive function in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving executive function in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving executive function in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0233] In another embodiment, a method for improving executive function in Alzheimer's disease subjects with mild cognitive impairment (MCI), comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subjects, is provided herein. In some embodiments, a method for improving executive function in Alzheimer's disease subjects with mild cognitive impairment (MCI), comprising administering compound 1 to the subjects, is provided herein. In some embodiments This specification provides a method for improving executive function in subjects with mild cognitive impairment (MCI) and Alzheimer's disease, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0234] In another embodiment, a method for improving executive function in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subjects. In some embodiments, a method for improving executive function in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering compound 1 to the subjects. In some embodiments, a method for improving executive function in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subjects. In some embodiments, compound 1 is administered to the subjects daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0235] In one embodiment, a method for improving working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, the subject A method for improving working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0236] In one embodiment, a method for improving working memory in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving working memory in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving working memory in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0237] In another embodiment, a method for improving working memory in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving working memory in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving working memory in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0238] In another embodiment, a method for improving working memory in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving working memory in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving working memory in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, compound 1 The pharmaceutically acceptable salts are administered orally.
[0239] In another embodiment, a method for improving working memory in subjects with mild cognitive impairment (MCI) of Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subjects. In some embodiments, a method for improving working memory in subjects with mild cognitive impairment (MCI) of Alzheimer's disease is provided herein, comprising administering compound 1 to the subjects. In some embodiments, a method for improving working memory in subjects with mild cognitive impairment (MCI) of Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subjects. In some embodiments, compound 1 is administered to the subjects daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0240] In another embodiment, a method for improving working memory in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subjects. In some embodiments, a method for improving working memory in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering compound 1 to the subjects. In some embodiments, a method for improving working memory in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subjects. In some embodiments, compound 1 is administered to the subjects daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 The salt is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0241] In one embodiment, a method for improving learning in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving learning in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving learning in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0242] In one embodiment, a method for improving learning in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving learning in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving learning in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof A pharmaceutically acceptable salt is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0243] In another embodiment, a method for improving learning in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving learning in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving learning in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0244] In another embodiment, a method for improving learning in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving learning in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving learning in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. It is administered to elephants. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0245] In another embodiment, a method for improving learning in subjects with mild cognitive impairment (MCI) and Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subjects. In some embodiments, a method for improving learning in subjects with mild cognitive impairment (MCI) and Alzheimer's disease is provided herein, comprising administering compound 1 to the subjects. In some embodiments, a method for improving learning in subjects with mild cognitive impairment (MCI) and Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subjects. In some embodiments, compound 1 is administered to the subjects daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0246] In another embodiment, a method for improving learning in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subjects. In some embodiments, a method for improving learning in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering compound 1 to the subjects. In some embodiments, a method for improving learning in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subjects. In some embodiments, compound 1 is administered to the subjects daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. A pharmaceutically acceptable salt is administered to the subject at a dose of 0.3–6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3–6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3–6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0247] In one embodiment, a method for improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject in a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0248] In one embodiment, a method for improving learning and working memory in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving learning and working memory in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving learning and working memory in a subject having mild cognitive impairment associated with Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a subject at a dose of approximately 3 mg / day. Compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0249] In another embodiment, a method for improving learning and working memory in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving learning and working memory in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving learning and working memory in a subject having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally.In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0250] In another embodiment, a method for improving learning and working memory in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, a method for improving learning and working memory in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering compound 1 to the subject. In some embodiments, a method for improving learning and working memory in a subject having mild cognitive impairment due to Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subject. In some embodiments, compound 1 is administered to the subject daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is The compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0251] In another embodiment, a method for improving learning and working memory in subjects with mild cognitive impairment (MCI) and Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subjects. In some embodiments, a method for improving learning and working memory in subjects with mild cognitive impairment (MCI) and Alzheimer's disease is provided herein, comprising administering compound 1 to the subjects. In some embodiments, a method for improving learning and working memory in subjects with mild cognitive impairment (MCI) and Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subjects. In some embodiments, compound 1 is administered to the subjects daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subjects at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0252] In another embodiment, a method for improving learning and working memory in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering compound 1 or a pharmaceutically acceptable salt thereof to the subjects. In some embodiments, a method for improving learning and working memory in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering compound 1 to the subjects. In some embodiments, a method for improving learning and working memory in subjects with mild cognitive impairment of Alzheimer's disease is provided herein, comprising administering a pharmaceutically acceptable salt of compound 1 to the subjects. In some embodiments, compound 1 is administered to the subjects daily. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subjects daily. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is administered orally. In some embodiments, a pharmaceutically acceptable salt of compound 1 is administered orally.
[0253] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day.In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. Several embodiments. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, pharmaceutically acceptable salts of compound 1 are intended for oral administration.
[0254] In some embodiments, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for treating mild cognitive impairment associated with Alzheimer's disease in a subject is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for treating mild cognitive impairment associated with Alzheimer's disease in a subject is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for treating mild cognitive impairment associated with Alzheimer's disease in a subject is provided herein. In some embodiments, compound 1 is for daily administration to a subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to a subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day.In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug comprises 0.1 to 1.0 mg of compound 1. In some embodiments, the drug comprises 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, The drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for oral administration.
[0255] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for treating mild cognitive impairment (MCI) caused by Alzheimer's disease in a subject is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for treating mild cognitive impairment (MCI) caused by Alzheimer's disease in a subject is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for treating mild cognitive impairment (MCI) caused by Alzheimer's disease in a subject is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day.In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for oral administration.
[0256] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for treating mild dementia caused by Alzheimer's disease in a subject is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for treating mild dementia caused by Alzheimer's disease in a subject is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for treating mild dementia caused by Alzheimer's disease in a subject is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day.In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for oral administration.
[0257] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for treating mild cognitive impairment (MCI) in subjects having Alzheimer's disease is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for treating mild cognitive impairment (MCI) in subjects having Alzheimer's disease is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for treating mild cognitive impairment (MCI) in subjects having Alzheimer's disease is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day.In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for oral administration.
[0258] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for treating mild cognitive impairment in subjects with Alzheimer's disease is provided herein. In some embodiments, the use of compound 1 or a pharmaceutically acceptable salt thereof for treating mild cognitive impairment in subjects with Alzheimer's disease is provided herein. The use of compound 1 for the manufacture of a drug for the purpose of [details omitted] is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for the treatment of mild dementia in subjects having Alzheimer's disease is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for administration to a subject at a dose of about 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended for administration to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended for administration to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for administration to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended for administration to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for administration to a subject at a dose of 3 mg / day. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1.In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for oral administration.
[0259] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof is provided herein for the manufacture of a drug for improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. In some embodiments, the use of compound 1 is provided herein for the manufacture of a drug for improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 is provided herein for the manufacture of a drug for improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. In some embodiments, compound 1 is intended for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is intended for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended for administration to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 is intended for administration to the subject at a dose of about 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for administration to the subject at a dose of about 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended for administration to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1.In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, the pharmaceutically acceptable salt of compound 1 is for oral administration.
[0260] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment associated with Alzheimer's disease is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment associated with Alzheimer's disease is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment associated with Alzheimer's disease is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of approximately 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1.In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for oral administration.
[0261] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment (MCI) due to Alzheimer's disease is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or its pharmaceutically acceptable The salt is intended for administration to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is intended for administration to the subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for administration to the subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended for administration to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended for administration to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for administration to the subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended for administration to the subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended for administration to the subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended for administration to the subject at a dose of 3 mg / day. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof.In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1. In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for oral administration.
[0262] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment due to Alzheimer's disease is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment due to Alzheimer's disease is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for improving executive function in subjects having mild cognitive impairment due to Alzheimer's disease is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of about 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of about 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of about 3 mg / day. In some embodiments In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.1 to 1.0 mg of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 0.5 mg of compound 1. In some embodiments, the drug contains 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains 1.0 mg of compound 1.In some embodiments, the drug contains 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, compound 1 is for oral administration. In some embodiments, the pharmaceutically acceptable salt of compound 1 is for oral administration.
[0263] In one embodiment, the use of compound 1 or a pharmaceutically acceptable salt thereof for the manufacture of a drug for improving executive function in subjects with Alzheimer's disease having mild cognitive impairment (MCI) is provided herein. In some embodiments, the use of compound 1 for the manufacture of a drug for improving executive function in subjects with Alzheimer's disease having mild cognitive impairment (MCI) is provided herein. In some embodiments, the use of a pharmaceutically acceptable salt of compound 1 for the manufacture of a drug for improving executive function in subjects with Alzheimer's disease having mild cognitive impairment (MCI) is provided herein. In some embodiments, compound 1 is for daily administration to the subject. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for daily administration to the subject. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is for administration to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of approximately 3 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 0.3 to 6 mg / day. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, a pharmaceutically acceptable salt of compound 1 is intended to be administered to a subject at a dose of 3 mg / day. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.1 to about 1.0 mg of compound 1. In some embodiments, the drug contains about 0.1 to about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 0.5 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 0.5 mg of compound 1. In some embodiments, the drug contains about 0.5 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains about 1.0 mg of compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the drug contains about 1.0 mg of compound 1. In some embodiments, the drug contains about 1.0 mg of a pharmaceutically acceptable salt of compound 1. In some embodiments, the drug contains 0.1 to 1.0 mg of com...
Claims
[Claim 1] The invention described in the specification.
